

=> fil re

'RE' IS AN AMBIGUOUS FILE OR CLUSTER NAME
REACTION - Reactions Cluster
RESEARCH - Research Cluster
REGISTRY - The CAS Registry File of substances
ENTER FILE OR CLUSTER NAME (IGNORE):reg
FILE 'REGISTRY' ENTERED AT 07:59:54 ON 17 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 14 APR 2006 HIGHEST RN 880516-92-7
DICTIONARY FILE UPDATES: 14 APR 2006 HIGHEST RN 880516-92-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> d que l2

L1 587 SEA FILE=REGISTRY ABB=ON PLU=ON RKRRKR/SQSP
L2 26 SEA FILE=REGISTRY ABB=ON PLU=ON L1 AND SQL<21

See 1

=> fil caplus

FILE 'CAPLUS' ENTERED AT 08:00:01 ON 17 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the

American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Apr 2006 VOL 144 ISS 17
FILE LAST UPDATED: 16 Apr 2006 (20060416/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> d que 14

L1 587 SEA FILE=REGISTRY ABB=ON PLU=ON RKRRKR/SQSP
L2 26 SEA FILE=REGISTRY ABB=ON PLU=ON L1 AND SQL<21
L4 26 SEA FILE=CAPLUS ABB=ON PLU=ON L2

=> d .ca hitstr 14 1-26

L4 ANSWER 1 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1291766 CAPLUS
DOCUMENT NUMBER: 144:40715
TITLE: Modified antiviral nucleases for prevention and treatment of viral diseases
INVENTOR(S): Salganik, Rudolf I.; Appelbaum, Jacob G.
PATENT ASSIGNEE(S): Avirid Biotechnology, LLC, USA
SOURCE: PCT Int. Appl., 145 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005115444	A2	20051208	WO 2005-US12532	20050414
<p>W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW</p> <p>RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG</p>				

PRIORITY APPLN. INFO.: US 2004-561934P P 20040414
ED Entered STN: 09 Dec 2005
AB Antiviral compns. comprising a modified nuclease, or a plurality of such modified nucleases having at least one non-natural amino acid residue substituted for a naturally occurring amino acid in a parent nuclease are provided, as are methods of use and kits providing unit dosages of such compns.
IC ICM A61K038-46
CC 63-3 (Pharmaceuticals)
Section cross-reference(s): 1, 3, 7, 13

IT 95088-49-6P 146849-86-7P 185846-63-3P 188842-14-0P 189036-95-1P
 197901-72-7P 209408-51-5P 211106-37-5P 216017-89-9P 220961-91-1P
 220961-92-2P 220961-93-3P 221295-48-3P 251375-94-7P 371755-42-9P
 371755-43-0P 395069-86-0P 521076-79-9P 521076-81-3P 607741-80-0P
 622403-07-0P 675171-13-8P 762302-30-7P 762302-31-8P
 762302-34-1P 762302-36-3P 845869-25-2P 845869-26-3P 845869-29-6P
 845869-30-9P 870789-33-6P 870789-34-7P 870789-35-8P 870789-36-9P
 870789-37-0P 870789-38-1P 870789-39-2P 870789-40-5P 870789-41-6P
 870789-42-7P 870789-43-8P 870803-52-4P 870803-53-5P 870803-54-6P
 870803-55-7P 870803-56-8P 870803-57-9P 870803-58-0P 870803-59-1P
 870803-60-4P 870803-61-5P

RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (antiviral peptide sequence; modified antiviral nucleases for prevention and treatment of viral diseases)

IT 675171-13-8P


RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (antiviral peptide sequence; modified antiviral nucleases for prevention and treatment of viral diseases)


RN 675171-13-8 CAPLUS

CN L-Leucine, L-methionyl-L-leucyl-L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-lysyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





L4 ANSWER 2 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:984044 CAPLUS
 DOCUMENT NUMBER: 143:279342
 TITLE: Peptides derived from heparan sulphate proteoglycan (HSPG) receptor binding region or LDL receptor binding region of an apolipoprotein for treatment of bacterial infections
 INVENTOR(S): Dobson, Curtis; Crutcher, Keith Alan
 PATENT ASSIGNEE(S): The University of Manchester, UK
 SOURCE: PCT Int. Appl., 74 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005082399	A2	20050909	WO 2005-GB769	20050228
WO 2005082399	A3	20051222		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 2004-4374 A 20040227

OTHER SOURCE(S): MARPAT 143:279342

ED Entered STN: 09 Sep 2005

AB The invention relates to polypeptides or analog comprising repeats of peptides derived from apolipoproteins, which exhibit antibacterial activity. The invention further provides the uses of peptides derived from a heparan sulfate proteoglycan (HSPG) receptor-binding region or LDL receptor-binding domain cluster B of apolipoprotein B or apolipoprotein E in methods of preventing or treating bacterial infection. An object selected from medical devices, lenses, contact lenses, catheters, stents, wound healing dressings, contraceptives, surgical implants, and replacement joints is coated with the apolipoprotein derived peptides for treating bacterial contamination. A hospital ward surfaces, operating theater surfaces, kitchen surfaces and sanitary surfaces are coated with apolipoprotein-derived peptides for treating bacterial contamination.

IC ICM A61K038-17

CC 1-5 (Pharmacology)

IT 99287-08-8 121798-56-9 856008-75-8 856008-78-1 856008-79-2

856009-00-2	856009-19-3	856009-21-7	856009-23-9	856009-24-0
856009-26-2	856009-28-4	856009-29-5	856009-31-9	856009-38-6
857631-58-4	864070-05-3	864070-06-4	864070-07-5	
864070-10-0	864070-11-1	864106-45-6	864106-46-7	864106-47-8
864106-48-9	864106-49-0	864106-50-3	864106-51-4	864106-52-5
864106-53-6	864106-54-7	864106-55-8	864106-56-9	864106-57-0
864106-58-1	864106-59-2	864106-60-5	864106-61-6	864106-62-7
864106-63-8	864106-64-9			

RL: PRP (Properties)

(unclaimed sequence; peptides derived from heparan sulfate proteoglycan (HSPG) receptor-binding region or LDL receptor-binding region of apolipoprotein for treatment of bacterial infections)

IT **864070-07-5**

RL: PRP (Properties)


(unclaimed sequence; peptides derived from heparan sulfate proteoglycan (HSPG) receptor-binding region or LDL receptor-binding region of apolipoprotein for treatment of bacterial infections)

RN 864070-07-5 CAPLUS


CN L-Arginine, L-arginyl-L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-lysyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



NH PAGE 2-A





L4 ANSWER 3 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:570928 CAPLUS
 DOCUMENT NUMBER: 143:90981
 TITLE: ApoE-derived peptides for treatment of viral infections
 INVENTOR(S): Dobson, Curtis
 PATENT ASSIGNEE(S): The University of Manchester, UK
 SOURCE: PCT Int. Appl., 54 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005058959	A2	20050630	WO 2004-GB5360	20041217
WO 2005058959	A3	20051215		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 2003-29254 A 20031217

ED Entered STN: 01 Jul 2005


AB The invention discloses polypeptides derived from a tandem repeat of apoE141-149 and their uses as medicaments. The peptides may comprise the tandem repeat, and truncations thereof, for which at least one leucine is replaced by an amino acid with a side chain comprising at least 4 carbon atoms and at least one nitrogen atom. Such peptides are useful for preventing or treating viral infections.



IC ICM C07K014-77


CC 1-5 (Pharmacology)
 IT 98805-74-4 116591-61-8 144601-92-3 174793-00-1 205941-25-9
 670225-89-5 670225-91-9 670225-92-0 670225-93-1 856008-65-6
 856008-67-8 856008-68-9 856008-69-0 856008-70-3 856008-71-4
 856008-72-5 856008-73-6 856008-74-7 856008-75-8 856008-77-0
 856008-78-1 856008-79-2 856008-80-5 856008-81-6 856008-82-7
 856008-83-8 856008-84-9 856008-88-3 856008-90-7 856008-92-9
 856008-94-1 856008-96-3 856008-98-5 856008-99-6 856009-00-2
 856009-01-3 856009-02-4 856009-03-5 856009-04-6 856009-05-7
 856009-06-8 856009-07-9 856009-08-0 856009-09-1 856009-10-4
 856009-11-5 856009-12-6 856009-13-7 856009-14-8 856009-15-9
 856009-16-0 856009-17-1 **856009-18-2** 856009-19-3
 856009-20-6 856009-21-7 856009-22-8 856009-23-9 856009-24-0
 856009-25-1 856009-26-2 856009-27-3 856009-28-4 856009-29-5
 856009-30-8 856009-31-9 856009-32-0 856009-33-1 856009-34-2
 856009-35-3 856009-36-4 856009-37-5 856009-38-6 856009-39-7
 856009-40-0
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (apoE-derived peptides for treatment of viral infections)
 IT **856009-18-2**
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (apoE-derived peptides for treatment of viral infections)
 RN 856009-18-2 CAPLUS
 CN L-Arginine, L-arginyl-L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-arginyl-L-lysyl-L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-lysyl-L-arginyl-L-lysyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







L4 ANSWER 4 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:141241 CAPLUS
 DOCUMENT NUMBER: 142:234435
 TITLE: Targeted carrier fusions for delivery of
 chemotherapeutic agents
 INVENTOR(S): Shen, Ben
 PATENT ASSIGNEE(S): Wisconsin Alumni Research Foundation, USA
 SOURCE: PCT Int. Appl., 109 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005014823	A2	20050217	WO 2004-US25376	20040805
WO 2005014823	A3	20050721		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2534708	AA	20050217	CA 2004-2534708	20040805
US 2005059122	A1	20050317	US 2004-912764	20040805
PRIORITY APPLN. INFO.:			US 2003-492508P	P 20030805
			WO 2004-US25376	W 20040805

ED Entered STN: 18 Feb 2005

AB The present invention provides for fusion proteins that act as targeted drug carriers. The present invention provides method of producing a fusion protein comprising a drug-binding portion of a carrier polypeptide and a cell targeting protein. The drug may be selected from the group consisting of an antibiotic, a plant alkaloid, an alkylating agent, a DNA repair inhibitor or a DNA cleaving agent. The cell targeting peptide targets a cancer cell such as pancreatic cancer cell, liver cancer cell, lymphoma cell, myeloma cell, neuroblastoma cell, breast cancer cell, prostate cancer cell, or a head & neck cancer cell. The carrier protein is an apolipoprotein, a binding protein or a natural or synthetic variant

therof, such as cagA or NscA. The binding protein derived from a biosynthetic gene cluster protein, such as BlmA, PlmA, or MRD, or a pathogen drug-resistance protein. The proteins are derived from mols. that possess natural drug-binding capabilities that are further engineered to target specific cell types, and optionally to have altered/improved drug binding characteristics. These fusion proteins are useful in, for example, delivery of chemotherapeutic compds. to cancer cells.

IC ICM C12N015-62

CC 3-2 (Biochemical Genetics)

Section cross-reference(s): 1, 6

IT 149635-29-0 168179-57-5 189023-64-1 205117-83-5 205117-84-6
 222720-10-7 241478-23-9 241478-24-0 243961-51-5 243961-52-6
 264260-44-8 272121-15-0 281194-44-3 284039-31-2 286378-93-6
 359636-54-7 362043-77-4 386223-83-2 390817-54-6 444890-48-6
 444890-49-7 444890-50-0 444890-51-1 444890-52-2 444890-53-3
 444890-54-4 444890-55-5 444890-56-6 478167-40-7 845527-02-8
 845527-03-9 845527-04-0 845527-05-1 845527-06-2 845527-07-3
 845527-08-4 845527-09-5 845527-10-8 845527-11-9 845527-12-0
 845527-13-1 845527-14-2 845527-15-3 **845527-16-4**
 845527-17-5 845591-68-6 845591-69-7 845591-70-0 845591-71-1
 845591-72-2 845591-73-3 845591-74-4 845591-75-5

RL: PRP (Properties)

(unclaimed sequence; targeted carrier fusions for delivery of chemotherapeutic agents)

IT **845527-16-4**

RL: PRP (Properties)



(unclaimed sequence; targeted carrier fusions for delivery of chemotherapeutic agents)

RN 845527-16-4 CAPLUS


CN L-Lysine, L-leucyl-L-arginyl-L-isoleucyl-L-lysyl-L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-lysyl-L-arginyl-L-lysyl-L-lysyl-L-threonyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 2-A



PAGE 3-A



PAGE 4-A



L4 ANSWER 5 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:526353 CAPLUS
 DOCUMENT NUMBER: 141:291982
 TITLE: Positively charged synthetic peptides from structural proteins of papillomaviruses abrogate human papillomavirus infectivity
 AUTHOR(S): Bousarghin, Latifa; Touze, Antoine; Yvonnet, Bernard; Coursaget, Pierre

CORPORATE SOURCE: Laboratoire de Virologie Moleculaire, INSERM U618,
Faculte de Pharmacie, Tours, Fr.

SOURCE: Journal of Medical Virology (2004), 73(3), 474-480
CODEN: JMVIDB; ISSN: 0146-6615

PUBLISHER: Wiley-Liss, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 01 Jul 2004

AB Human papillomavirus (HPV) virus-like particles (VLP) and synthetic peptides corresponding to pos.-charged sequences of the major and minor capsid proteins were tested for their efficacy in inhibiting the infectivity of HPV 31 pseudovirions by blocking virus entry into cells. A greater than 80% reduction of transfection was observed with one HPV-31 peptide at a concentration of 10 µg/mL. Moreover, the blocking was not type-specific since similar reduction in transfection was observed with peptides from other

HPV types at a concentration of 60 µg/mL. This concentration was non-toxic for the cells. These findings indicate that some of the pos.-charged sequences of the L1 and L2 HPV capsid proteins of papillomavirus are compds. that might be locally active against sexually transmitted papillomavirus. The findings provide further evidence that cellular glycosaminoglycans (GAGs) are functional receptors for HPVs.

CC 10-2 (Microbial, Algal, and Fungal Biochemistry)
Section cross-reference(s): 1

IT 675171-13-8 762302-30-7 762302-31-8 762302-32-9
762302-33-0 762302-34-1 762302-35-2 762302-36-3
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pos. charged synthetic peptides from structural proteins of papillomaviruses abrogate human papillomavirus infectivity)


IT 675171-13-8
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pos. charged synthetic peptides from structural proteins of papillomaviruses abrogate human papillomavirus infectivity)

RN 675171-13-8 CAPLUS


CN L-Leucine, L-methionyl-L-leucyl-L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-lysyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:267714 CAPLUS
 DOCUMENT NUMBER: 140:286151
 TITLE: Alternative reading frame (ncORF) antigenic determinants from viruses and uses in vaccines
 INVENTOR(S): Mattner, Frank; Schmidt, Walter; Habel, Andre
 PATENT ASSIGNEE(S): Intercell A.-G., Austria
 SOURCE: PCT Int. Appl., 220 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 7
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004011650	A2	20040205	WO 2003-XA8112	20030724

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG

WO 2004011650 A2 20040205 WO 2003-EP8112 20030724
WO 2004011650 A3 20040624

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: AT 2002-1124 A 20020724
EP 2003-450171 A 20030711
WO 2003-EP8112 A 20030724

ED Entered STN: 02 Apr 2004

AB It is an object of the present invention to provide means for replacing or improving existing or proposed vaccines against viral pathogens, especially human pathogens. A specific aim is to provide effective T cell epitopes against viral pathogens. The invention discloses polypeptides encoded by an alternative reading frame (non-coding open-reading frame (ncORF)) of a pathogenic virus, which polypeptides - start with a methionine amino acid residue, - comprise an antigenic determinant (epitope) and - comprise more than 7 amino acid residues and fragments of said polypeptides comprising more than 7 amino acids. T cell responses against alternatively encoded epitopes are detectable in patients suffering such infections. Such a polypeptide according to the present invention may be defined as an antigenic sequence outside the primarily (main) transcribed ORF of a given pathogenic virus. Alternatively encoded antigens from hepatitis C virus and human immunodeficiency virus are provided. Possible ncORF epitopes with superior immunization properties were identified for hepatitis C virus (HCV), human immunodeficiency virus (HIV) and human papilloma virus (HPV). The immunogenicity of HCV ncORF peptides was demonstrated on HLA-A-allele-transgenic mice and on HCV patient -derived cells.

IC ICM C12N015-33
ICS C07K014-005; C07K014-18; A61K039-12

CC 15-2 (Immunochemistry)

Section cross-reference(s): 3, 10

IT 675169-10-5 675169-11-6 675169-12-7 675169-13-8 675169-14-9
675169-15-0 675169-16-1 675169-17-2 675169-18-3 675169-19-4
675169-20-7 675169-21-8 675169-22-9 675169-23-0 675169-24-1
675169-25-2 675169-26-3 675169-27-4 675169-28-5 675169-29-6
675169-30-9 675169-31-0 675169-32-1 675169-33-2 675169-34-3
675169-35-4 675169-36-5 675169-37-6 675169-38-7 675169-39-8
675169-40-1 675169-41-2 675169-42-3 675169-43-4 675169-44-5
675169-45-6 675169-46-7 675169-47-8 675169-48-9 675169-49-0
675169-50-3 675169-51-4 675169-52-5 675169-53-6 675169-54-7
675169-55-8 675169-56-9 675169-57-0 675169-58-1 675169-59-2
675169-60-5 675169-61-6 675169-62-7 675169-63-8 675169-64-9
675169-65-0 675169-66-1 675169-67-2 675169-68-3 675169-69-4

675169-70-7	675169-71-8	675169-72-9	675169-73-0	675169-74-1
675169-75-2	675169-76-3	675169-77-4	675169-78-5	675169-79-6
675169-80-9	675169-81-0	675169-82-1	675169-83-2	675169-84-3
675169-85-4	675169-86-5	675169-87-6	675169-88-7	675169-89-8
675169-90-1	675169-91-2	675169-94-5	675169-95-6	675169-96-7
675169-97-8	675169-98-9	675169-99-0	675170-00-0	675170-01-1
675170-02-2	675170-03-3	675170-04-4	675170-05-5	675170-06-6
675170-07-7	675170-08-8	675170-09-9	675170-10-2	675170-11-3
675170-12-4	675170-13-5	675170-14-6	675170-15-7	675170-16-8
675170-17-9	675170-18-0	675170-19-1	675170-20-4	675170-21-5
675170-22-6	675170-23-7	675170-24-8	675170-25-9	675170-26-0
675170-27-1	675170-28-2	675170-29-3	675170-30-6	675170-31-7
675170-32-8	675170-33-9	675170-34-0	675170-35-1	675170-36-2
675170-37-3	675170-38-4	675170-39-5	675170-40-8	675170-41-9
675170-42-0	675170-43-1	675170-44-2	675170-45-3	675170-46-4
675170-47-5	675170-48-6	675170-49-7	675170-50-0	675170-51-1
675170-52-2	675170-53-3	675170-54-4	675170-55-5	675170-56-6
675170-57-7	675170-58-8	675170-59-9	675170-60-2	
675170-61-3	675170-62-4	675170-63-5	675170-64-6	675170-65-7
675170-66-8	675170-67-9	675170-68-0	675170-69-1	675170-70-4
675170-71-5	675170-72-6	675170-73-7	675170-74-8	675170-75-9
675170-76-0	675170-77-1	675170-78-2	675170-79-3	675170-80-6
675170-81-7	675170-82-8	675170-83-9	675170-84-0	675170-85-1
675170-86-2	675170-87-3	675170-88-4	675170-89-5	675170-90-8
675170-91-9	675170-92-0	675170-93-1	675170-94-2	675170-95-3
675170-96-4	675170-97-5	675170-98-6	675170-99-7	675171-00-3
675171-01-4	675171-02-5	675171-03-6	675171-04-7	675171-05-8
675171-06-9	675171-07-0	675171-08-1	675171-10-5	675171-11-6
675171-13-8	675171-15-0	675171-17-2	675171-19-4	
675171-20-7	675171-22-9	675171-24-1	675171-25-2	675171-26-3
675171-30-9	675171-32-1	675171-33-2	675171-35-4	675171-36-5
675171-38-7	675171-40-1	675171-43-4	675171-45-6	675171-46-7
675171-48-9	675171-49-0	675171-51-4	675171-54-7	675171-57-0
675171-58-1	675171-60-5	675171-62-7	675171-63-8	675171-64-9
675171-67-2	675171-68-3	675171-70-7	675171-72-9	675171-74-1
675171-76-3	675171-78-5	675171-80-9		

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(amino acid sequence; alternative reading frame (ncORF) antigenic determinants from viruses and uses in vaccines)

IT	675171-82-1	675171-83-2	675171-84-3	675171-85-4	675171-88-7
	675171-90-1	675171-92-3	675171-94-5	675171-96-7	675172-00-6
	675172-03-9	675172-06-2	675172-09-5	675172-11-9	
	675172-13-1	675172-15-3	675172-17-5	675172-19-7	675172-21-1
	675172-25-5	675172-28-8	675172-30-2	675172-32-4	675172-37-9
	675172-38-0	675172-40-4	675172-42-6	675172-44-8	675172-46-0
	675172-48-2	675172-50-6	675172-53-9	675172-55-1	675172-57-3
	675172-59-5	675172-61-9	675172-63-1	675172-65-3	675172-67-5
	675172-69-7	675172-71-1	675172-73-3	675172-75-5	675172-77-7
	675172-79-9	675172-81-3	675172-82-4	675172-84-6	675172-86-8
	675172-88-0	675172-90-4	675172-92-6	675172-94-8	675172-97-1
	675172-99-3	675173-02-1	675173-05-4	675173-07-6	675173-09-8
	675173-11-2	675173-14-5	675173-16-7	675173-18-9	675173-20-3
	675173-22-5	675173-24-7	675173-26-9	675173-28-1	675173-30-5
	675173-32-7	675173-34-9	675173-36-1	675173-39-4	675173-42-9
	675173-44-1	675173-46-3	675173-48-5	675173-50-9	675173-52-1
	675173-55-4	675173-57-6	675173-59-8	675173-61-2	675173-63-4
	675173-65-6	675173-67-8	675173-69-0	675173-71-4	675173-73-6
	675173-75-8	675173-78-1	675173-80-5	675173-82-7	675173-85-0
	675173-87-2	675173-90-7	675173-92-9	675173-94-1	675173-97-4

675173-99-6	675174-02-4	675174-04-6	675174-07-9	675174-09-1
675174-11-5	675174-13-7	675174-15-9	675174-17-1	675174-19-3
675174-21-7	675174-23-9	675174-25-1	675174-27-3	675174-30-8
675174-33-1	675174-36-4	675174-37-5	675174-38-6	675174-39-7
675174-40-0	675174-41-1	675174-42-2	675174-43-3	675174-45-5
675174-46-6	675174-47-7	675174-48-8	675174-49-9	675174-50-2
675174-51-3	675174-52-4	675174-53-5	675174-54-6	675174-55-7
675174-56-8	675174-57-9	675174-58-0	675174-59-1	675174-60-4
675174-61-5	675174-62-6	675174-63-7	675174-64-8	675174-65-9
675174-66-0	675174-67-1	675174-68-2	675174-69-3	675174-70-6
675174-71-7	675174-72-8	675174-73-9	675174-74-0	675174-75-1
675174-76-2	675174-77-3	675174-78-4	675174-79-5	675174-80-8
675174-81-9	675174-82-0	675174-83-1	675174-84-2	675174-85-3
675174-86-4	675174-87-5	675174-88-6	675174-89-7	675174-90-0
675174-91-1	675174-92-2	675174-93-3	675174-94-4	675174-95-5
675174-96-6	675174-97-7	675174-98-8	675174-99-9	675175-00-5
675175-01-6	675175-02-7	675175-03-8	675175-04-9	675175-05-0
675175-06-1	675175-07-2	675175-08-3	675175-09-4	675175-10-7
675175-11-8	675175-12-9	675175-13-0	675175-14-1	675175-15-2
675175-16-3	675175-17-4	675175-18-5	675175-19-6	675175-20-9
675175-21-0	675175-22-1	675175-23-2	675175-24-3	675175-25-4
675175-26-5	675175-27-6	675175-28-7	675175-29-8	675175-30-1
675175-31-2	675175-32-3	675175-33-4	675175-34-5	675175-35-6
675175-36-7	675175-37-8	675175-38-9	675175-39-0	675175-40-3
675175-41-4	675175-42-5	675175-43-6	675175-44-7	675175-45-8
675175-46-9	675175-47-0	675175-48-1	675175-49-2	675175-50-5
675175-51-6	675175-52-7	675175-53-8	675175-54-9	675175-55-0
675175-56-1	675175-57-2			

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(amino acid sequence; alternative reading frame (ncORF) antigenic determinants from viruses and uses in vaccines)

IT 675170-59-9 675171-13-8 675172-00-6
675172-03-9

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(amino acid sequence; alternative reading frame (ncORF) antigenic determinants from viruses and uses in vaccines)

RN 675170-59-9 CAPLUS


CN L-Leucine, L-leucyl-L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-lysyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 675171-13-8 CAPLUS


CN L-Leucine, L-methionyl-L-leucyl-L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-lysyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 675172-00-6 CAPLUS


CN L-Leucine, L-tyrosyl-L-methionyl-L-leucyl-L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-lysyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 675172-03-9 CAPLUS


CN L-Tyrosine, L-leucyl-L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-lysyl-L-arginyl-L-leucyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L4 ANSWER 7 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:951189 CAPLUS
 DOCUMENT NUMBER: 140:13048
 TITLE: Compositions and methods for hemophilia A gene therapy
 using recombinant human factor VIII
 INVENTOR(S): High, Katherine A.; Camire, Rodney M.
 PATENT ASSIGNEE(S): The Children's Hospital of Philadelphia, USA
 SOURCE: PCT Int. Appl., 57 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003100053	A1	20031204	WO 2003-US16376	20030522
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003241599	A1	20031212	AU 2003-241599	20030522
US 2004005670	A1	20040108	US 2003-445235	20030522
PRIORITY APPLN. INFO.:			US 2002-382486P	P 20020522
			WO 2003-US16376	W 20030522

ED Entered STN: 07 Dec 2003

AB Improved materials and methods for the treatment of Hemophilia A are provided. Specifically, recombinant human factor VIII with deletions between amino acid 740, or 730, or 720 to 1689, which lacks some of A2 and B-domain of heavy chain, and some of A3 domain of light chain, are disclosed for Hemophilia A gene therapy. Also provided are minigene constructs expressing two fragments of factor VIII with a linker peptide, RRRR or RKRRKR, which containing PACE-furin cleavage sites. These recombinant factor VIII expressed in mammalian cell lines have 5-13-fold greater activity in a one-stage APTT clotting assay compared to rFVIII-SQ (a reported shortest version of FVIII gene), which lacks the major part of the central B-domain.

IC ICM C12N015-00

ICS C12N015-63; A61K038-54; A61K035-14; A61K048-00

CC 1-8 (Pharmacology)

Section cross-reference(s): 3, 6, 14

IT 26791-46-8 360764-74-5

RL: BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)

(PACE furin or PACE furin-like cleavage site; compns. and methods for hemophilia A gene therapy using recombinant human factor VIII)

IT 360764-74-5

RL: BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)


(PACE furin or PACE furin-like cleavage site; compns. and methods for hemophilia A gene therapy using recombinant human factor VIII)

RN 360764-74-5 CAPLUS


CN L-Arginine, L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:857457 CAPLUS
 DOCUMENT NUMBER: 137:380985
 TITLE: Human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
 INVENTOR(S): Jakobovits, Aya; Challita-Eid, Pia M.; Faris, Mary; Ge, Wangmao; Hubert, Rene S.; Morrison, Karen; Morrison, Robert Kendall; Raitano, Arthur B.
 PATENT ASSIGNEE(S): Agensys, Inc., USA
 SOURCE: PCT Int. Appl., 1021 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 30
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083921	A2	20021024	WO 2002-XO11654	20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,				

BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 WO 2002083921 A2 20021024 WO 2002-US11654 20020410
 WO 2002083921 C1 20051215

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, UZ, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG,
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 2005227253 A1 20051013 US 2004-990137 20041115
 US 2006018917 A1 20060126 US 2004-989767 20041115
 US 2005214211 A1 20050929 US 2005-73349 20050303

PRIORITY APPLN. INFO.:

US 2001-282739P P 20010410
 US 2001-283112P P 20010410
 US 2001-286630P P 20010425
 WO 2002-US11654 A 20020410
 US 2000-227098P P 20000822
 US 2001-300373P P 20010622
 US 2001-935430 A1 20010822
 US 2002-120835 A3 20020409

ED Entered STN: 12 Nov 2002

AB Eighteen genes and their resp. encoded proteins, and variants thereof, are described wherein the gene exhibits restricted expression in normal adult tissue and is overexpressed in various cancers. Suppression subtractive hybridization (SSH) is used to identify cDNAs corresponding to genes that are differentially expressed in cancer; PCR amplification, cloning, and sequencing of gene fragments from SSH yield the full-length cDNAs. Consequently, the gene products provide diagnostic, prognostic, prophylactic, and/or therapeutic targets for cancer. The genes or fragment thereof, their encoded proteins, or variants or fragments thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with the gene products can be used in active or passive immunization. [This abstract record is one of 16 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IC ICM C12Q

CC 3-3 (Biochemical Genetics)

Section cross-reference(s): 1, 6, 9, 14

IT 474749-02-5 474749-03-6 474749-04-7 474749-05-8 474749-06-9
 474749-07-0 474749-08-1 474749-11-6 **474749-12-7**
 474749-13-8 474749-16-1 474749-17-2 474749-19-4 474749-20-7
 474749-21-8 474749-22-9 474749-24-1 474749-27-4 474749-31-0
 474749-36-5 474749-38-7 474749-46-7 474749-47-8 474749-48-9
 474749-49-0 474749-50-3 474749-51-4 474749-52-5 474749-53-6
 474749-54-7 474749-56-9 474749-59-2 474749-61-6 474749-62-7
 474749-63-8 474749-65-0 474749-66-1 474749-69-4 474749-70-7
 474749-73-0 474749-74-1 474749-75-2 474749-80-9 474749-81-0
 474749-83-2 474749-85-4 474749-86-5 474749-89-8 474749-93-4
 474749-95-6 474749-96-7 474749-99-0 474750-00-0 474750-04-4
 474750-06-6 474750-09-9 474750-11-3 474750-13-5 474750-14-6
 474750-16-8 474750-21-5 474750-67-9 474750-69-1 474750-70-4
 474750-71-5 474750-74-8 474750-75-9 474750-76-0 474750-77-1
 474750-78-2 474750-79-3 474750-80-6 474750-81-7 474750-82-8
 474750-86-2 474750-87-3 474750-88-4 474750-91-9 474750-96-4
 474750-97-5 474751-00-3 474751-01-4 474751-05-8 474751-06-9
 474751-11-6 474751-12-7 474751-13-8 474751-15-0 474751-16-1

474751-17-2	474751-18-3	474751-19-4	474751-20-7	474751-22-9
474751-23-0	474751-25-2	474751-26-3	474751-27-4	474751-28-5
474751-32-1	474751-33-2	474751-34-3	474751-36-5	474751-38-7
474751-39-8	474751-46-7	474751-50-3	474751-51-4	474751-52-5
474751-55-8	474751-56-9	474751-58-1	474751-67-2	474751-68-3
474751-70-7	474751-71-8	474751-72-9	474751-73-0	474751-77-4
474751-80-9	474751-82-1	474751-83-2	474751-90-1	474751-92-3
474751-94-5	474751-95-6	474751-99-0	474752-04-0	474752-05-1
474752-07-3	474752-09-5	474752-10-8	474752-14-2	474752-16-4
474752-19-7	474752-21-1	474752-27-7	474752-30-2	474752-31-3
474752-32-4	474752-37-9	474752-40-4	474752-42-6	474752-43-7
474752-44-8	474752-50-6	474752-51-7	474752-55-1	474752-57-3
474752-58-4	474752-63-1	474752-71-1	474752-72-2	474752-74-4
474752-78-8	474752-82-4	474752-94-8	474752-99-3	474753-02-1
474753-03-2	474753-07-6	474753-09-8	474753-16-7	474753-23-6
474753-25-8	474753-34-9	474753-35-0	474753-36-1	474753-39-4
474753-46-3	474753-49-6	474753-53-2	474753-54-3	474753-55-4
474753-56-5	474753-77-0	474753-86-1	474753-90-7	474754-01-3
474754-04-6	474754-07-9	474754-15-9	474754-16-0	474754-23-9
474754-25-1	474754-35-3	474754-37-5	474754-46-6	474754-55-7
474754-58-0	474754-59-1	474754-70-6	474754-71-7	474754-75-1
474754-86-4	474754-95-5	474754-96-6	474755-05-0	474755-08-3
474755-10-7	474755-12-9	474755-14-1	474755-17-4	474755-24-3
474755-25-4	474755-26-5	474755-27-6	474755-28-7	474755-29-8
474755-33-4	474755-34-5	474755-36-7	474755-40-3	474755-44-7
474755-45-8	474755-48-1	474755-53-8	474755-54-9	474755-62-9
474755-64-1	474755-71-0	474755-73-2	474755-77-6	474755-87-8
474755-88-9	474756-02-0	474756-09-7	474756-10-0	474756-11-1
474756-12-2	474756-17-7	474756-18-8		

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

IT	474883-30-2	474883-31-3	474883-35-7	474883-37-9	474883-41-5
	474883-45-9	474883-47-1	474883-48-2	474883-50-6	474883-52-8
	474883-53-9	474883-67-5	474883-70-0	474883-75-5	474883-77-7
	474883-78-8	474883-79-9	474883-80-2	474883-81-3	474883-84-6
	474883-85-7	474883-87-9	474883-88-0	474883-89-1	474883-90-4
	474883-91-5	474883-92-6	474883-96-0	474883-97-1	474884-00-9
	474884-02-1	474884-03-2	474884-06-5	474884-09-8	474884-11-2
	474884-17-8	474884-18-9	474884-20-3	474884-28-1	
	474884-32-7	474884-39-4	474884-40-7	474884-68-9	474884-74-7
	474884-75-8	474884-78-1	474884-79-2	474884-80-5	474884-82-7
	474884-86-1	474885-14-8	474885-15-9	474885-16-0	474885-17-1
	474885-18-2	474885-37-5	474885-39-7	474885-40-0	474885-41-1
	474885-44-4	474885-47-7	474885-54-6	474885-55-7	474885-57-9
	474885-58-0	474885-73-9	474885-74-0	474885-76-2	474885-77-3
	474885-82-0	474885-84-2	474885-98-8	474886-01-6	474886-02-7
	474886-03-8	474886-04-9	474886-08-3	474886-09-4	474886-10-7
	474886-11-8	474886-12-9	474886-13-0	474886-14-1	474886-15-2
	474886-16-3	474886-17-4	474886-19-6	474886-21-0	474886-22-1
	474886-23-2	474886-25-4	474886-31-2	474886-33-4	474886-36-7
	474886-37-8	474886-39-0	474886-40-3	474886-41-4	474886-42-5
	474886-43-6	474886-44-7	474886-45-8	474886-46-9	474886-47-0
	474886-50-5	474886-55-0	474886-57-2	474886-59-4	474886-60-7
	474886-61-8	474886-63-0	474886-64-1	474886-68-5	474886-69-6
	474886-71-0	474886-72-1	474886-74-3	474886-75-4	474886-78-7
	474886-79-8	474886-80-1	474886-81-2	474886-82-3	474886-83-4
	474886-91-4	474886-92-5	474887-02-0	474887-09-7	474887-11-1

474887-13-3	474887-15-5	474887-16-6	474887-20-2	474887-21-3
474887-22-4	474887-27-9	474887-41-7	474887-42-8	474887-45-1
474887-46-2	474887-47-3	474887-49-5	474887-51-9	474887-52-0
474887-54-2	474887-69-9	474887-75-7	474887-80-4	474887-81-5
474887-82-6	474887-89-3	474887-90-6	474887-97-3	474888-01-2
474888-06-7	474888-10-3	474888-15-8	474888-28-3	474908-85-5
474908-88-8	474908-89-9	474908-90-2	474909-02-9	474909-03-0
474909-04-1	474909-05-2	474909-06-3	474909-08-5	474909-11-0
474909-12-1	474909-13-2	474909-14-3	474909-15-4	474909-16-5
474909-17-6	474909-19-8	474909-20-1	474909-21-2	474909-22-3
474909-24-5	474909-25-6	474909-27-8	474909-29-0	474909-30-3
474909-31-4	474909-32-5	474909-33-6	474909-34-7	474909-36-9
474909-37-0	474909-38-1	474909-39-2	474909-42-7	474909-50-7
474909-53-0	474909-57-4	474909-58-5	474909-59-6	474909-61-0
474909-66-5	474909-67-6	474909-68-7	474909-69-8	474909-70-1
474909-71-2	474909-72-3	474909-80-3	474909-81-4	474909-82-5
474909-85-8	474909-87-0	474909-91-6	474909-92-7	474909-93-8
474909-94-9	474909-96-1	474910-01-5	474910-03-7	474910-04-8
474910-05-9	474910-10-6	474910-12-8	474910-14-0	474910-15-1
474910-16-2	474910-17-3	474910-20-8	474910-23-1	474910-39-9
474910-46-8	474910-52-6	474910-95-7		

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

IT **474749-12-7 474884-20-3**

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)


(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

RN 474749-12-7 CAPLUS


CN L-Cysteine, L-leucyl-L-alanyl-L-cysteinyl-L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-lysyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 474884-20-3 CAPLUS


CN L-Methionine, L-alanyl-L-cysteinyl-L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-lysyl-L-arginyl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L4 ANSWER 9 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:857455 CAPLUS
 DOCUMENT NUMBER: 137:380984
 TITLE: Human nucleic acids and corresponding proteins useful
 in the detection and treatment of various cancers
 INVENTOR(S): Jakobovits, Aya; Challita-Eid, Pia M.; Faris, Mary;
 Ge, Wangmao; Hubert, Rene S.; Morrison, Karen;
 Morrison, Robert Kendall; Raitano, Arthur B.
 PATENT ASSIGNEE(S): Agensys, Inc., USA
 SOURCE: PCT Int. Appl., 1021 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 30
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083921	A2	20021024	WO 2002-XN11654	20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2002083921	A2	20021024	WO 2002-US11654	20020410
WO 2002083921	C1	20051215		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, UZ, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG,
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 2005227253	A1	20051013	US 2004-990137	20041115
US 2006018917	A1	20060126	US 2004-989767	20041115
US 2005214211	A1	20050929	US 2005-73349	20050303

PRIORITY APPLN. INFO.:

US 2001-282739P	P	20010410
US 2001-283112P	P	20010410
US 2001-286630P	P	20010425
WO 2002-US11654	A	20020410
US 2000-227098P	P	20000822
US 2001-300373P	P	20010622
US 2001-935430	A1	20010822
US 2002-120835	A3	20020409

ED Entered STN: 12 Nov 2002

AB Eighteen genes and their resp. encoded proteins, and variants thereof, are described wherein the gene exhibits restricted expression in normal adult tissue and is overexpressed in various cancers. Suppression subtractive hybridization (SSH) is used to identify cDNAs corresponding to genes that are differentially expressed in cancer; PCR amplification, cloning, and sequencing of gene fragments from SSH yield the full-length cDNAs. Consequently, the gene products provide diagnostic, prognostic, prophylactic, and/or therapeutic targets for cancer. The genes or fragment thereof, their encoded proteins, or variants or fragments thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with the gene products can be used in active or passive immunization. [This abstract record is one of 16 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IC ICM C12Q

CC 3-3 (Biochemical Genetics)

Section cross-reference(s): 1, 6, 9, 14

IT 474841-02-6	474841-03-7	474841-05-9	474841-19-5	474841-20-8
474841-21-9	474841-23-1	474841-24-2	474841-29-7	474841-30-0

474841-31-1	474841-32-2	474841-35-5	474841-36-6	474841-37-7
474841-38-8	474841-40-2	474841-41-3	474841-42-4	474841-43-5
474841-47-9	474841-48-0	474841-50-4	474841-52-6	474841-55-9
474841-56-0	474841-58-2	474841-60-6	474841-90-2	474841-92-4
474841-95-7	474841-97-9	474841-98-0	474842-01-8	474842-03-0
474842-16-5	474842-22-3	474842-30-3	474842-32-5	474842-37-0
474842-38-1	474842-40-5	474842-41-6	474842-42-7	474842-44-9
474842-45-0	474842-47-2	474842-48-3	474842-50-7	474842-57-4
474842-64-3	474842-65-4	474842-66-5	474842-70-1	474842-71-2
474842-74-5	474842-79-0	474842-80-3	474842-85-8	474842-90-5
474842-93-8	474842-96-1	474843-00-0	474843-03-3	474843-06-6
474843-07-7	474843-10-2	474843-11-3	474843-13-5	474843-15-7
474843-17-9	474843-18-0	474890-55-6	474890-56-7	474890-57-8
474890-71-6	474890-73-8	474890-77-2	474890-82-9	474890-84-1
474890-97-6	474891-43-5	474891-48-0	474891-56-0	474891-58-2
474891-61-7	474891-67-3	474891-76-4	474891-91-3	474891-94-6
474892-00-7	474892-02-9	474892-07-4	474892-10-9	474892-12-1
474892-14-3	474892-21-2	474892-28-9	474892-47-2	474892-50-7
474892-53-0	474892-57-4	474892-61-0	474892-63-2	474892-68-7
474892-77-8	474892-89-2	474892-92-7	474892-99-4	474893-02-2
474893-10-2	474893-12-4	474893-14-6	474893-16-8	474893-18-0
474893-20-4	474893-22-6	474893-26-0	474893-30-6	474893-36-2
474893-42-0	474893-46-4	474893-61-3	474893-63-5	474893-69-1
474893-73-7	474893-80-6	474893-84-0	474893-88-4	474894-00-3
474894-03-6	474894-05-8	474894-09-2	474894-20-7	474894-34-3
474894-48-9	474894-53-6	474894-76-3	474894-79-6	474894-81-0
474894-83-2	474895-00-6	474896-06-5	474896-96-3	
474897-14-8	474897-19-3	474897-23-9	474897-24-0	474897-25-1
474897-30-8	474897-31-9	474897-32-0	474897-36-4	474897-37-5
474897-38-6	474897-39-7	474897-48-8	474897-50-2	474897-87-5
474897-89-7	474897-90-0	474897-92-2	474897-93-3	474897-94-4
474897-95-5	474897-96-6	474897-97-7	474897-98-8	474897-99-9
474898-00-5	474898-01-6	474898-02-7	474898-03-8	474898-07-2
474898-08-3	474898-09-4	474898-10-7	474898-11-8	474898-14-1
474898-15-2	474898-18-5	474898-22-1	474898-26-5	474898-27-6
474898-28-7	474898-29-8	474898-30-1	474898-33-4	474898-34-5
474898-35-6	474898-37-8	474898-38-9	474898-39-0	474898-40-3
474898-41-4	474898-42-5	474898-43-6	474898-46-9	474898-47-0
474898-48-1	474898-51-6	474898-52-7	474898-54-9	474898-55-0
474898-56-1	474898-57-2	474898-60-7	474898-66-3	474898-68-5
474898-70-9	474898-71-0	474898-72-1	474898-73-2	474898-74-3
474898-75-4	474898-77-6	474898-83-4	474898-84-5	474898-85-6
474898-86-7	474898-88-9	474898-93-6	474898-96-9	474898-97-0
474898-98-1	474899-07-5	474899-08-6	474899-09-7	474899-10-0
474899-11-1	474899-18-8	474899-19-9		

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

IT **474894-34-3 474895-00-6**

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)


(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

RN 474894-34-3 CAPLUS


CN L-Cysteine, L-alanyl-L-cysteinyl-L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-lysyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 474895-00-6 CAPLUS


CN L-Methionine, L-cysteinyl-L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-lysyl-L-arginyl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L4 ANSWER 10 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:857454 CAPLUS
 DOCUMENT NUMBER: 137:380983
 TITLE: Human nucleic acids and corresponding proteins useful
 in the detection and treatment of various cancers
 INVENTOR(S): Jakobovits, Aya; Challita-Eid, Pia M.; Faris, Mary;
 Ge, Wangmao; Hubert, Rene S.; Morrison, Karen;
 Morrison, Robert Kendall; Raitano, Arthur B.
 PATENT ASSIGNEE(S): Agensys, Inc., USA
 SOURCE: PCT Int. Appl., 1021 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 30
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083921	A2	20021024	WO 2002-XM11654	20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, UZ, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 WO 2002083921 A2 20021024 WO 2002-US11654 20020410
 WO 2002083921 C1 20051215
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, UZ, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG,
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 US 2005227253 A1 20051013 US 2004-990137 20041115
 US 2006018917 A1 20060126 US 2004-989767 20041115
 US 2005214211 A1 20050929 US 2005-73349 20050303
 PRIORITY APPLN. INFO.:
 US 2001-282739P P 20010410
 US 2001-283112P P 20010410
 US 2001-286630P P 20010425
 WO 2002-US11654 A 20020410
 US 2000-227098P P 20000822
 US 2001-300373P P 20010622
 US 2001-935430 A1 20010822
 US 2002-120835 A3 20020409
 ED Entered STN: 12 Nov 2002
 AB Eighteen genes and their resp. encoded proteins, and variants thereof, are described wherein the gene exhibits restricted expression in normal adult tissue and is overexpressed in various cancers. Suppression subtractive hybridization (SSH) is used to identify cDNAs corresponding to genes that are differentially expressed in cancer; PCR amplification, cloning, and sequencing of gene fragments from SSH yield the full-length cDNAs. Consequently, the gene products provide diagnostic, prognostic, prophylactic, and/or therapeutic targets for cancer. The genes or fragment thereof, their encoded proteins, or variants or fragments thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with the gene products can be used in active or passive immunization. [This abstract record is one of 16 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].
 IC ICM C12Q
 CC 3-3 (Biochemical Genetics)
 Section cross-reference(s): 1, 6, 9, 14
 IT 473786-54-8 473786-55-9 473786-66-2 473786-67-3 473786-68-4
 473786-69-5 473786-70-8 473786-71-9 473786-76-4 473786-78-6
 473786-80-0 473786-84-4 473786-85-5 473786-86-6 473786-88-8
 473786-90-2 473786-92-4 473786-94-6 473787-13-2 473787-24-5
 473787-27-8 473787-32-5 473787-36-9 473787-49-4 473787-51-8
 473787-58-5 473787-60-9 473787-61-0 473787-62-1 473787-65-4
 473787-67-6 473787-82-5 473787-88-1 473787-89-2 473788-03-3
 473788-07-7 473788-12-4 473788-13-5 473788-21-5 473788-29-3
 473788-50-0 473788-52-2 473788-85-1 473789-02-5 473789-25-2
 473789-42-3 473789-77-4 473790-17-9 473790-20-4 473790-30-6
 473790-40-8 473790-50-0 473790-57-7 473790-92-0 473791-01-4

473791-03-6	473791-13-8	473791-33-2	473791-53-6	473791-57-0
473791-65-0	473791-78-5	473791-82-1	473791-94-5	473791-97-8
473792-00-6	473792-03-9	473792-08-4	473792-11-9	473792-19-7
473792-28-8	473792-35-7	473792-39-1	473792-40-4	473792-52-8
473792-56-2	473792-59-5	473792-74-4	473792-96-0	473793-02-1
473793-03-2	473793-07-6	473793-09-8	473793-39-4	473793-55-4
473793-58-7	473793-60-1	473793-64-5	473793-70-3	473793-72-5
473793-73-6	473793-76-9	473793-82-7	473793-93-0	473793-94-1
473793-95-2	473793-96-3	473793-99-6	473794-00-2	473794-04-6
473794-13-7	473794-14-8	473794-17-1	473794-19-3	473794-25-1
473794-28-4	473794-29-5	473794-40-0	473794-43-3	473794-49-9
473794-50-2	473794-54-6	473794-56-8	473794-58-0	473794-66-0
473794-67-1	473794-68-2	473794-72-8	473794-74-0	473794-75-1
473794-77-3	474291-05-9	474746-17-3	474746-18-4	474746-19-5
474746-20-8	474746-21-9	474746-22-0	474746-24-2	474746-25-3
474746-27-5	474746-28-6	474746-29-7	474746-30-0	474746-33-3
474746-34-4	474746-35-5	474746-36-6	474746-37-7	474746-38-8
474746-41-3	474746-43-5	474746-44-6	474746-46-8	474746-47-9
474746-48-0	474746-50-4	474746-51-5	474746-52-6	474746-53-7
474746-54-8	474746-55-9	474746-56-0	474746-57-1	474746-58-2
474746-59-3	474746-61-7	474746-62-8	474746-63-9	474746-68-4
474746-75-3	474746-77-5	474746-82-2	474746-83-3	474746-85-5
474746-87-7	474746-88-8	474746-93-5	474747-02-9	474747-05-2
474747-09-6	474747-12-1	474747-14-3	474747-18-7	474747-26-7
474747-41-6	474747-42-7	474747-44-9	474747-49-4	474747-50-7
474747-51-8	474747-60-9	474747-64-3	474747-65-4	474747-66-5
474747-67-6	474747-70-1	474747-73-4	474747-86-9	474747-89-2
474747-94-9	474747-97-2	474748-01-1	474748-14-6	474748-16-8
474748-31-7	474748-40-8	474748-48-6	474748-56-6	474748-61-3
474748-71-5	474748-72-6	474748-76-0	474748-79-3	474748-80-6
474748-84-0	474748-87-3	474748-88-4	474748-89-5	474748-91-9
474748-92-0	474748-93-1	474748-94-2	474748-95-3	474748-96-4
474748-97-5	474748-98-6	474748-99-7	474749-00-3	474749-02-5
474749-03-6	474749-04-7	474749-05-8	474749-06-9	474749-07-0
474749-08-1	474749-11-6	474749-12-7	474749-13-8	
474749-16-1	474749-17-2	474749-18-3		

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

IT	474794-26-8	474794-33-7	474794-77-9	474794-81-5	474794-89-3
	474794-94-0	474794-99-5	474795-00-1	474795-05-6	474795-06-7
	474795-08-9	474795-09-0	474795-10-3	474795-12-5	474795-28-3
	474795-34-1	474795-47-6	474795-82-9	474795-94-3	474796-47-9
	474796-60-6	474796-71-9	474796-79-7	474796-89-9	474796-91-3
	474797-04-1	474797-29-0	474797-47-2	474797-53-0	474797-68-7
	474797-72-3	474816-14-3	474833-29-9	474833-31-3	474833-33-5
	474833-34-6	474833-35-7	474833-38-0	474833-39-1	474833-66-4
	474833-88-0	474834-04-3	474834-12-3	474834-13-4	474834-18-9
	474834-19-0	474834-22-5	474834-32-7	474834-33-8	474834-37-2
	474835-00-2	474835-12-6	474835-13-7	474835-20-6	474835-24-0
	474835-26-2	474835-28-4	474835-88-6	474835-90-0	474835-96-6
	474836-25-4	474836-40-3	474836-73-2	474836-78-7	474836-81-2
	474836-84-5	474837-12-2	474837-35-9	474837-50-8	474837-73-5
	474837-82-6	474837-94-0	474838-41-0	474838-95-4	474839-19-5
	474839-36-6	474839-69-5	474839-73-1	474839-83-3	474840-22-7
	474840-66-9	474840-75-0	474840-77-2	474840-85-2	474840-90-9
	474882-55-8	474882-56-9	474882-59-2	474882-60-5	474882-61-6
	474882-63-8	474882-64-9	474882-65-0	474882-67-2	474882-68-3

474882-70-7	474882-77-4	474882-81-0	474883-00-6	474883-02-8
474883-04-0	474883-05-1	474883-07-3	474883-09-5	474883-15-3
474883-20-0	474883-21-1	474883-22-2	474883-24-4	474883-25-5
474883-26-6	474883-30-2	474883-32-4	474883-35-7	474883-36-8
474883-38-0	474883-41-5	474883-42-6	474883-44-8	474883-45-9
474883-46-0	474883-48-2	474883-49-3	474883-50-6	474883-52-8
474883-59-5	474883-63-1	474883-67-5	474883-69-7	474883-70-0
474883-71-1	474883-74-4	474883-75-5	474883-77-7	474883-78-8
474883-79-9	474883-80-2	474883-81-3	474883-82-4	474883-84-6
474883-85-7	474883-86-8	474883-87-9	474883-88-0	474883-89-1
474883-90-4	474883-91-5	474883-92-6	474883-93-7	474883-94-8
474883-95-9	474883-96-0	474884-09-8	474884-11-2	474884-17-8
474884-18-9	474884-20-3	474884-60-1	474884-62-3	
474884-63-4	474884-64-5	474884-68-9	474884-70-3	474884-75-8
474884-78-1	474884-79-2	474884-80-5	474884-81-6	474884-82-7
474884-86-1	474884-88-3	474884-90-7	474884-91-8	474884-94-1
474884-96-3	474885-01-3	474885-02-4	474885-14-8	474885-15-9
474885-16-0	474885-17-1	474885-18-2	474885-41-1	474885-44-4
474885-46-6	474885-48-8	474885-50-2	474885-54-6	474885-58-0
474885-60-4	474885-68-2	474885-70-6	474885-72-8	474885-74-0
474885-76-2	474885-77-3	474885-78-4	474885-79-5	474885-81-9
474885-82-0	474885-94-4	474885-96-6	474885-97-7	474885-98-8
474886-01-6	474886-02-7	474886-03-8	474886-04-9	474886-05-0
474886-08-3	474886-09-4	474886-10-7	474886-11-8	474886-13-0
474886-14-1	474886-15-2	474886-16-3	474886-17-4	474886-22-1
474886-23-2	474886-29-8	474886-31-2	474886-34-5	474886-35-6
474886-36-7	474886-37-8	474886-39-0	474886-40-3	474886-41-4
474886-42-5	474886-43-6	474886-45-8		

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

IT 474749-12-7 474884-20-3

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)


(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

RN 474749-12-7 CAPLUS


CN L-Cysteine, L-leucyl-L-alanyl-L-cysteinyl-L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-lysyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 474884-20-3 CAPLUS


CN L-Methionine, L-alanyl-L-cysteinyl-L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-lysyl-L-arginyl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L4 ANSWER 11 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:857453 CAPLUS
 DOCUMENT NUMBER: 137:380982
 TITLE: Human nucleic acids and corresponding proteins useful
 in the detection and treatment of various cancers
 INVENTOR(S): Jakobovits, Aya; Challita-Eid, Pia M.; Faris, Mary;
 Ge, Wangmao; Hubert, Rene S.; Morrison, Karen;
 Morrison, Robert Kendall; Raitano, Arthur B.
 PATENT ASSIGNEE(S): Agensys, Inc., USA
 SOURCE: PCT Int. Appl., 1021 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 30
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083921	A2	20021024	WO 2002-XL11654	20020410
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2002083921	A2	20021024	WO 2002-US11654	20020410
WO 2002083921	C1	20051215		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
US 2005227253	A1	20051013	US 2004-990137	20041115
US 2006018917	A1	20060126	US 2004-989767	20041115
US 2005214211	A1	20050929	US 2005-73349	20050303
PRIORITY APPLN. INFO.:			US 2001-282739P	P 20010410
			US 2001-283112P	P 20010410
			US 2001-286630P	P 20010425
			WO 2002-US11654	A 20020410
			US 2000-227098P	P 20000822
			US 2001-300373P	P 20010622
			US 2001-935430	A1 20010822
			US 2002-120835	A3 20020409

ED Entered STN: 12 Nov 2002

AB Eighteen genes and their resp. encoded proteins, and variants thereof, are described wherein the gene exhibits restricted expression in normal adult tissue and is overexpressed in various cancers. Suppression subtractive hybridization (SSH) is used to identify cDNAs corresponding to genes that are differentially expressed in cancer; PCR amplification, cloning, and sequencing of gene fragments from SSH yield the full-length cDNAs. Consequently, the gene products provide diagnostic, prognostic, prophylactic, and/or therapeutic targets for cancer. The genes or fragment thereof, their encoded proteins, or variants or fragments thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with the gene products can be used in active or passive immunization. [This abstract record is one of 16 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IC ICM C12Q

CC 3-3 (Biochemical Genetics)

Section cross-reference(s): 1, 6, 9, 14

IT	134605-99-5	151812-32-7	265665-73-4	473314-20-4	473314-21-5
	473314-22-6	473314-23-7	473314-25-9	473314-27-1	473314-29-3

473314-30-6	473314-33-9	473314-34-0	473314-36-2	473314-37-3
473314-38-4	473314-39-5	473314-40-8	473314-42-0	473314-43-1
473314-44-2	473314-45-3	473314-46-4	473314-47-5	473314-49-7
473314-50-0	473314-52-2	473314-53-3	473314-54-4	473314-59-9
473314-61-3	473314-64-6	473314-66-8	473314-67-9	473314-68-0
473314-69-1	473314-70-4	473314-71-5	473314-72-6	473314-74-8
473314-75-9	473314-76-0	473314-79-3	473314-80-6	473314-81-7
473314-82-8	473314-89-5	473314-92-0	473314-94-2	473315-01-4
473315-02-5	473315-03-6	473315-04-7	473315-06-9	473315-07-0
473315-09-2	473315-10-5	473315-13-8	473315-15-0	473315-16-1
473315-18-3	473315-19-4	473315-23-0	473315-24-1	473315-26-3
473315-30-9	473315-32-1	473315-34-3	473315-36-5	473315-38-7
473315-40-1	473315-41-2	473315-44-5	473315-46-7	473315-48-9
473315-49-0	473315-50-3	473315-51-4	473315-54-7	473315-55-8
473315-57-0	473315-58-1	473315-59-2	473315-60-5	473315-65-0
473315-66-1	473315-67-2	473315-68-3	473315-69-4	473315-71-8
473315-73-0	473315-74-1	473315-75-2	473315-76-3	473315-77-4
473315-78-5	473315-82-1	473315-83-2	473315-84-3	473315-85-4
473315-86-5	473315-87-6	473315-88-7	473315-89-8	473315-90-1
473315-91-2	473315-92-3	473315-93-4	473315-94-5	473315-95-6
473315-99-0	473316-00-6	473316-01-7	473316-02-8	473316-06-2
473316-07-3	473316-09-5	473316-10-8	473316-14-2	473316-16-4
473316-17-5	473316-19-7	473317-07-6	473317-18-9	473317-43-0
473317-47-4	473317-60-1	473317-62-3	473317-80-5	473317-93-0
473318-03-5	473318-31-9	473318-36-4	473318-38-6	473318-43-3
473318-45-5	473318-48-8	473318-54-6	473318-56-8	473318-57-9
473318-63-7	473318-64-8	473318-68-2	473318-86-4	473318-87-5
473318-89-7	473318-90-0	473318-91-1	473318-92-2	473318-93-3
473318-95-5	473318-96-6	473318-98-8	473318-99-9	473319-00-5
473319-02-7	473319-03-8	473319-04-9	473319-05-0	473319-06-1
473319-08-3	473319-09-4	473319-10-7	473319-12-9	
473319-13-0	473319-14-1	473319-17-4	473319-18-5	473319-19-6
473319-20-9	473319-22-1	473319-23-2	473319-24-3	473319-25-4
473319-26-5	473319-27-6	473319-28-7	473319-29-8	473319-31-2
473319-32-3	473319-33-4	473319-34-5	473319-35-6	473319-36-7
473319-37-8	473319-38-9	473319-39-0	473319-40-3	473319-41-4
473319-42-5	473319-44-7	473319-45-8	473319-46-9	473319-47-0
473319-48-1	473319-49-2	473319-50-5	473319-51-6	473319-52-7
473319-53-8	473319-54-9	473319-55-0	473319-56-1	473319-57-2
473319-58-3	473319-59-4	473319-60-7	473319-61-8	473319-62-9
473319-63-0	473319-64-1	473319-65-2	473319-66-3	473319-67-4
473319-68-5	473319-69-6	473319-70-9	473319-71-0	473319-72-1
473319-73-2	473319-75-4	473319-76-5	473319-78-7	473319-80-1
473319-82-3	473319-83-4	473319-84-5	473319-86-7	473319-87-8
473319-88-9	473319-89-0	473319-90-3		

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

IT	474840-44-3	474840-46-5	474840-48-7	474840-49-8	474840-50-1
	474840-51-2	474840-52-3	474840-53-4	474840-54-5	474840-55-6
	474840-59-0	474840-63-6	474840-64-7	474840-65-8	474840-69-2
	474840-70-5	474840-71-6	474840-78-3	474840-79-4	474840-80-7
	474840-81-8	474840-82-9	474840-95-4	474840-96-5	474840-97-6
	474840-98-7	474840-99-8	474841-00-4	474841-01-5	474841-02-6
	474841-03-7	474841-19-5	474841-20-8	474841-21-9	474841-22-0
	474841-23-1	474841-24-2	474841-26-4	474841-27-5	474841-29-7
	474841-30-0	474841-31-1	474841-32-2	474841-34-4	474841-35-5
	474841-36-6	474841-37-7	474841-38-8	474841-40-2	474841-41-3

474841-42-4	474841-43-5	474841-46-8	474841-47-9	474841-48-0
474841-52-6	474841-55-9	474841-56-0	474841-73-1	474841-89-9
474841-90-2	474841-92-4	474841-95-7	474842-01-8	474842-03-0
474842-15-4	474842-16-5	474842-22-3	474842-24-5	474842-25-6
474842-27-8	474842-28-9	474842-29-0	474842-30-3	474842-34-7
474842-35-8	474842-37-0	474842-40-5	474842-41-6	474842-42-7
474842-44-9	474842-45-0	474842-46-1	474842-48-3	474842-50-7
474842-57-4	474842-59-6	474842-60-9	474842-62-1	474842-63-2
474842-64-3	474842-65-4	474842-67-6	474842-79-0	474842-80-3
474842-84-7	474842-85-8	474842-87-0	474842-89-2	474842-90-5
474842-93-8	474842-96-1	474842-97-2	474843-02-2	474843-06-6
474843-10-2	474843-11-3	474843-12-4	474843-19-1	474890-54-5
474890-55-6	474890-56-7	474890-57-8	474890-71-6	474890-73-8
474890-77-2	474890-82-9	474890-84-1	474890-97-6	474891-30-0
474891-36-6	474891-43-5	474891-48-0	474891-56-0	474891-58-2
474891-61-7	474891-63-9	474891-65-1	474891-67-3	474891-74-2
474891-76-4	474891-83-3	474891-87-7	474891-89-9	474891-91-3
474891-94-6	474892-00-7	474892-02-9	474892-07-4	474892-10-9
474892-12-1	474892-14-3	474892-17-6	474892-21-2	474892-28-9
474892-30-3	474892-32-5	474892-39-2	474892-42-7	474892-47-2
474892-50-7	474892-53-0	474892-57-4	474892-61-0	474892-63-2
474892-65-4	474892-68-7	474892-72-3	474892-77-8	474892-79-0
474892-89-2	474892-92-7	474892-99-4	474893-02-2	474893-10-2
474893-12-4	474893-14-6	474893-16-8	474893-18-0	474893-20-4
474893-22-6	474893-26-0	474893-30-6	474893-36-2	474893-42-0
474893-46-4	474893-59-9	474893-61-3	474893-63-5	474893-69-1
474893-73-7	474893-75-9	474893-77-1	474893-78-2	474893-80-6
474893-82-8	474893-84-0	474893-86-2	474893-88-4	474893-90-8
474893-94-2	474893-96-4	474893-98-6	474894-00-3	474894-03-6
474894-05-8	474894-09-2	474894-12-7	474894-15-0	474894-18-3
474894-20-7	474894-34-3	474894-48-9	474894-53-6	
474894-76-3	474894-78-5	474894-79-6	474894-81-0	474894-83-2
474894-98-9	474895-00-6	474895-07-3	474895-26-6	
474895-32-4	474896-06-5	474896-59-8	474896-96-3	474897-08-0
474897-09-1	474897-10-4	474897-12-6	474897-14-8	474897-15-9
474897-16-0	474897-17-1	474897-18-2	474897-19-3	474897-23-9
474897-24-0	474897-25-1	474897-26-2	474897-27-3	

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

IT **473319-12-9 474894-34-3 474895-00-6**

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)


(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

RN 473319-12-9 CAPLUS


CN L-Arginine, L-leucyl-L-alanyl-L-cysteinyl-L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 474894-34-3 CAPLUS
 CN L-Cysteine, L-alanyl-L-cysteinyl-L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-lysyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 2-A



RN 474895-00-6 CAPLUS

CN L-Methionine, L-cysteinyl-L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-lysyl-L-arginyl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 12 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:857452 CAPLUS
 DOCUMENT NUMBER: 137:380981
 TITLE: Human nucleic acids and corresponding proteins useful
 in the detection and treatment of various cancers
 INVENTOR(S): Jakobovits, Aya; Challita-Eid, Pia M.; Faris, Mary;
 Ge, Wangmao; Hubert, Rene S.; Morrison, Karen;
 Morrison, Robert Kendall; Raitano, Arthur B.
 PATENT ASSIGNEE(S): Agensys, Inc., USA
 SOURCE: PCT Int. Appl., 1021 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 30
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083921	A2	20021024	WO 2002-XK11654	20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, UZ, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 WO 2002083921 A2 20021024 WO 2002-US11654 20020410
 WO 2002083921 C1 20051215
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, UZ, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG,
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 US 2005227253 A1 20051013 US 2004-990137 20041115
 US 2006018917 A1 20060126 US 2004-989767 20041115
 US 2005214211 A1 20050929 US 2005-73349 20050303
 PRIORITY APPLN. INFO.: US 2001-282739P P 20010410
 US 2001-283112P P 20010410
 US 2001-286630P P 20010425
 WO 2002-US11654 A 20020410
 US 2000-227098P P 20000822
 US 2001-300373P P 20010622
 US 2001-935430 A1 20010822
 US 2002-120835 A3 20020409
 ED Entered STN: 12 Nov 2002
 AB Eighteen genes and their resp. encoded proteins, and variants thereof, are
 described wherein the gene exhibits restricted expression in normal adult
 tissue and is overexpressed in various cancers. Suppression subtractive
 hybridization (SSH) is used to identify cDNAs corresponding to genes that
 are differentially expressed in cancer; PCR amplification, cloning, and
 sequencing of gene fragments from SSH yield the full-length cDNAs.
 Consequently, the gene products provide diagnostic, prognostic,
 prophylactic, and/or therapeutic targets for cancer. The genes or
 fragment thereof, their encoded proteins, or variants or fragments
 thereof, can be used to elicit a humoral or cellular immune response;
 antibodies or T cells reactive with the gene products can be used in
 active or passive immunization. [This abstract record is one of 16 records
 for this document necessitated by the large number of index entries required
 to fully index the document and publication system constraints.]
 IC ICM C12Q
 CC 3-3 (Biochemical Genetics)
 Section cross-reference(s): 1, 6, 9, 14
 IT 474746-26-4 474746-27-5 474746-28-6 474746-29-7 474746-30-0
 474746-33-3 474746-34-4 474746-35-5 474746-36-6 474746-37-7
 474746-38-8 474746-41-3 474746-43-5 474746-46-8 474746-47-9
 474746-51-5 474746-52-6 474746-53-7 474746-55-9 474746-56-0
 474746-57-1 474746-59-3 474746-61-7 474746-62-8 474746-63-9
 474746-65-1 474746-66-2 474746-68-4 474746-75-3 474746-77-5
 474746-82-2 474746-83-3 474746-84-4 474746-85-5 474746-87-7
 474746-88-8 474746-95-7 474746-99-1 474747-02-9 474747-06-3
 474747-08-5 474747-12-1 474747-15-4 474747-17-6 474747-19-8
 474747-27-8 474747-41-6 474747-42-7 474747-44-9 474747-46-1
 474747-50-7 474747-54-1 474747-60-9 474747-64-3 474747-65-4

474747-67-6	474747-73-4	474747-85-8	474747-89-2	474747-94-9
474747-97-2	474748-01-1	474748-14-6	474748-16-8	474748-31-7
474748-42-0	474748-48-6	474748-55-5	474748-56-6	474748-61-3
474748-67-9	474748-71-5	474748-72-6	474748-79-3	474748-81-7
474748-84-0	474748-87-3	474748-88-4	474748-89-5	474748-91-9
474748-92-0	474748-94-2	474748-95-3	474748-96-4	474748-97-5
474748-98-6	474748-99-7	474749-00-3	474749-02-5	474749-03-6
474749-04-7	474749-05-8	474749-06-9	474749-07-0	474749-08-1
474749-11-6	474749-12-7	474749-13-8	474749-16-1	
474749-17-2	474749-19-4	474749-20-7	474749-21-8	474749-22-9
474749-24-1	474749-27-4	474749-31-0	474749-33-2	474749-36-5
474749-38-7	474749-42-3	474749-46-7	474749-47-8	474749-48-9
474749-49-0	474749-50-3	474749-51-4	474749-52-5	474749-53-6
474749-54-7	474749-56-9	474749-58-1	474749-59-2	474749-61-6
474749-62-7	474749-63-8	474749-65-0	474749-66-1	474749-69-4
474749-70-7	474749-71-8	474749-73-0	474749-74-1	474749-75-2
474749-81-0	474749-83-2	474749-85-4	474749-86-5	474749-87-6
474749-93-4	474749-95-6	474749-99-0	474750-00-0	474750-02-2
474750-04-4	474750-11-3	474750-12-4	474750-13-5	474750-14-6
474750-21-5	474750-24-8	474750-25-9	474750-26-0	474750-27-1
474750-28-2	474750-29-3	474750-31-7	474750-32-8	474750-33-9
474750-34-0	474750-35-1	474750-37-3	474750-39-5	474750-42-0
474750-43-1	474750-44-2	474750-45-3	474750-46-4	474750-47-5
474750-48-6	474750-50-0	474750-51-1	474750-52-2	474750-53-3
474750-55-5	474750-56-6	474750-57-7	474750-58-8	474750-59-9
474750-64-6	474750-66-8	474750-67-9	474750-68-0	474750-69-1
474750-72-6	474750-73-7	474750-74-8	474750-75-9	474750-76-0
474750-78-2	474750-79-3	474750-81-7	474750-82-8	474750-83-9
474750-86-2	474750-88-4	474750-90-8	474750-93-1	474750-97-5
474751-05-8	474751-08-1	474751-11-6	474751-12-7	474751-13-8
474751-14-9	474751-15-0	474751-16-1	474751-17-2	474751-18-3
474751-19-4	474751-20-7	474751-22-9	474751-23-0	474751-25-2
474751-26-3	474751-27-4	474751-28-5	474751-32-1	474751-33-2
474751-34-3	474751-36-5	474751-38-7	474751-39-8	474751-43-4
474751-46-7	474751-50-3	474751-51-4	474751-52-5	474751-55-8
474751-58-1	474751-67-2	474751-68-3		

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

IT	474883-37-9	474883-38-0	474883-39-1	474883-40-4	474883-41-5
	474883-42-6	474883-43-7	474883-44-8	474883-45-9	474883-46-0
	474883-47-1	474883-48-2	474883-49-3	474883-50-6	474883-51-7
	474883-52-8	474883-53-9	474883-54-0	474883-55-1	474883-56-2
	474883-57-3	474883-58-4	474883-59-5	474883-60-8	474883-61-9
	474883-62-0	474883-63-1	474883-64-2	474883-65-3	474883-66-4
	474883-67-5	474883-68-6	474883-69-7	474883-70-0	474883-71-1
	474883-72-2	474883-73-3	474883-74-4	474883-75-5	474883-76-6
	474883-77-7	474883-78-8	474883-79-9	474883-80-2	474883-81-3
	474883-82-4	474883-83-5	474883-84-6	474883-85-7	474883-86-8
	474883-87-9	474883-88-0	474883-89-1	474883-90-4	474883-91-5
	474883-92-6	474883-93-7	474883-94-8	474883-95-9	474883-96-0
	474883-97-1	474883-98-2	474883-99-3	474884-00-9	474884-01-0
	474884-02-1	474884-03-2	474884-04-3	474884-05-4	474884-06-5
	474884-07-6	474884-08-7	474884-09-8	474884-10-1	474884-11-2
	474884-12-3	474884-13-4	474884-14-5	474884-15-6	474884-16-7
	474884-17-8	474884-18-9	474884-19-0	474884-20-3	
	474884-22-5	474884-24-7	474884-28-1	474884-32-7	474884-39-4
	474884-40-7	474884-41-8	474884-53-2	474884-60-1	474884-61-2

474884-62-3	474884-63-4	474884-64-5	474884-65-6	474884-66-7
474884-67-8	474884-68-9	474884-69-0	474884-70-3	474884-71-4
474884-72-5	474884-73-6	474884-74-7	474884-75-8	474884-76-9
474884-77-0	474884-78-1	474884-79-2	474884-80-5	474884-81-6
474884-82-7	474884-83-8	474884-84-9	474884-85-0	474884-86-1
474884-87-2	474884-88-3	474884-89-4	474884-90-7	474884-91-8
474884-93-0	474884-94-1	474884-95-2	474884-96-3	474884-97-4
474885-01-3	474885-02-4	474885-13-7	474885-14-8	474885-15-9
474885-16-0	474885-17-1	474885-18-2	474885-19-3	474885-20-6
474885-21-7	474885-22-8	474885-23-9	474885-24-0	474885-25-1
474885-26-2	474885-27-3	474885-28-4	474885-29-5	474885-30-8
474885-31-9	474885-32-0	474885-33-1	474885-34-2	474885-35-3
474885-36-4	474885-37-5	474885-38-6	474885-39-7	474885-40-0
474885-41-1	474885-42-2	474885-43-3	474885-44-4	474885-45-5
474885-46-6	474885-47-7	474885-48-8	474885-49-9	474885-50-2
474885-51-3	474885-52-4	474885-53-5	474885-54-6	474885-55-7
474885-56-8	474885-57-9	474885-58-0	474885-59-1	474885-60-4
474885-61-5	474885-62-6	474885-63-7	474885-64-8	474885-65-9
474885-66-0	474885-67-1	474885-68-2	474885-69-3	474885-70-6
474885-71-7	474885-72-8	474885-73-9	474885-74-0	474885-75-1
474885-76-2	474885-77-3	474885-78-4	474885-79-5	474885-80-8
474885-81-9	474885-82-0	474885-83-1	474885-84-2	474885-85-3
474885-86-4	474885-87-5	474885-88-6	474885-89-7	474885-90-0
474885-91-1	474885-92-2	474885-93-3	474885-94-4	474885-95-5
474885-96-6	474885-97-7	474885-98-8	474885-99-9	474886-00-5
474886-01-6	474886-02-7	474886-03-8	474886-04-9	474886-05-0
474886-06-1	474886-07-2	474886-08-3	474886-09-4	474886-10-7
474886-11-8	474886-12-9	474886-13-0		

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

IT 474749-12-7 474884-20-3

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)


(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

RN 474749-12-7 CAPLUS


CN L-Cysteine, L-leucyl-L-alanyl-L-cysteinyl-L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-lysyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 474884-20-3 CAPLUS


CN L-Methionine, L-alanyl-L-cysteinyl-L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-lysyl-L-arginyl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L4 ANSWER 13 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:857450 CAPLUS
DOCUMENT NUMBER: 137:380979
TITLE: Human nucleic acids and corresponding proteins useful
in the detection and treatment of various cancers
INVENTOR(S): Jakobovits, Aya; Challita-Eid, Pia M.; Faris, Mary;
Ge, Wangmao; Hubert, Rene S.; Morrison, Karen;
Morrison, Robert Kendall; Raitano, Arthur B.
PATENT ASSIGNEE(S): Agensys, Inc., USA
SOURCE: PCT Int. Appl., 1021 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 30
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083921	A2	20021024	WO 2002-XI11654	20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2002083921	A2	20021024	WO 2002-US11654	20020410
WO 2002083921	C1	20051215		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2005227253	A1	20051013	US 2004-990137	20041115
US 2006018917	A1	20060126	US 2004-989767	20041115
US 2005214211	A1	20050929	US 2005-73349	20050303
PRIORITY APPLN. INFO.:				
			US 2001-282739P	P 20010410
			US 2001-283112P	P 20010410
			US 2001-286630P	P 20010425
			WO 2002-US11654	A 20020410
			US 2000-227098P	P 20000822
			US 2001-300373P	P 20010622
			US 2001-935430	A1 20010822
			US 2002-120835	A3 20020409
ED	Entered STN: 12 Nov 2002			
AB	Eighteen genes and their resp. encoded proteins, and variants thereof, are described wherein the gene exhibits restricted expression in normal adult tissue and is overexpressed in various cancers. Suppression subtractive hybridization (SSH) is used to identify cDNAs corresponding to genes that are differentially expressed in cancer; PCR amplification, cloning, and sequencing of gene fragments from SSH yield the full-length cDNAs. Consequently, the gene products provide diagnostic, prognostic, prophylactic, and/or therapeutic targets for cancer. The genes or fragment thereof, their encoded proteins, or variants or fragments thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with the gene products can be used in active or passive immunization. [This abstract record is one of 16 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].			
IC	ICM C12Q			
CC	3-3 (Biochemical Genetics)			
	Section cross-reference(s): 1, 6, 9, 14			
IT	99026-80-9	144722-25-8	168136-63-8	473775-84-7 473775-85-8
	473775-86-9	473775-88-1	473775-91-6	473775-92-7 473775-93-8

473775-94-9	473775-95-0	473775-96-1	473775-97-2	473775-98-3
473775-99-4	473776-00-0	473776-02-2	473776-03-3	473776-04-4
473776-05-5	473776-07-7	473776-08-8	473776-10-2	473776-12-4
473776-14-6	473776-15-7	473776-16-8	473776-17-9	473776-18-0
473776-19-1	473776-20-4	473776-21-5	473776-23-7	473776-24-8
473776-26-0	473776-29-3	473776-30-6	473776-32-8	473776-33-9
473776-34-0	473776-35-1	473776-36-2	473776-39-5	473776-41-9
473776-42-0	473776-43-1	473776-45-3	473776-46-4	473776-47-5
473776-49-7	473776-51-1	473776-52-2	473776-53-3	473776-56-6
473776-58-8	473776-59-9	473776-60-2	473776-61-3	473776-63-5
473776-64-6	473776-65-7	473776-66-8	473776-68-0	473776-71-5
473776-72-6	473776-79-3	473776-80-6	473776-84-0	473776-86-2
473776-88-4	473776-92-0	473776-94-2	473777-00-3	473777-06-9
473777-08-1	473777-10-5	473777-12-7	473777-13-8	473777-16-1
473777-17-2	473777-18-3	473777-19-4	473777-20-7	473777-22-9
473777-23-0	473777-25-2	473777-26-3	473777-28-5	473777-29-6
473777-30-9	473777-33-2	473777-36-5	473777-37-6	473777-38-7
473777-39-8	473777-40-1	473777-41-2	473777-44-5	473777-47-8
473777-49-0	473777-50-3	473777-53-6	473777-54-7	473777-55-8
473777-56-9	473777-57-0	473777-59-2	473777-62-7	473777-65-0
473777-67-2	473777-68-3	473777-69-4	473777-71-8	473777-75-2
473777-76-3	473777-77-4	473777-78-5	473777-79-6	473777-81-0
473777-82-1	473777-83-2	473777-84-3	473777-85-4	473777-86-5
473777-87-6	473777-88-7	473777-89-8	473777-90-1	473777-91-2
473777-92-3	473777-99-0	473778-00-6	473778-02-8	473778-04-0
473778-05-1	473778-06-2	473778-10-8	473778-17-5	473778-22-2
473778-36-8	473778-37-9	473778-38-0	473778-40-4	473778-41-5
473778-42-6	473778-47-1	473778-48-2	473778-56-2	473778-76-6
473778-84-6	473778-87-9	473778-96-0	473779-00-9	473779-03-2
473779-04-3	473779-06-5	473779-08-7	473779-12-3	473779-14-5
473779-15-6	473779-18-9	473779-22-5	473779-25-8	473779-29-2
473779-45-2	473779-46-3	473779-47-4	473779-48-5	473779-68-9
473779-69-0	473779-70-3	473779-73-6	473779-76-9	473779-79-2
473779-83-8	473779-85-0	473779-89-4	473779-93-0	473779-94-1
473779-95-2	473779-97-4	473779-98-5	473780-00-6	473780-02-8
473780-03-9	473780-05-1	473780-06-2	473780-07-3	473780-08-4
473780-09-5	473780-10-8	473780-12-0	473780-14-2	473780-15-3
473780-16-4	473780-17-5	473780-19-7	473780-20-0	473780-22-2
473780-23-3	473780-26-6	473780-27-7	473780-29-9	473780-30-2
473780-32-4	473780-33-5	473780-34-6	473780-36-8	
473780-39-1	473780-40-4	473780-43-7	473780-44-8	473780-45-9
473780-46-0	473780-49-3	473780-50-6	473780-51-7	473780-53-9
473780-54-0	473780-56-2	473780-61-9	473780-66-4	473780-67-5
473780-71-1	473780-72-2	473780-75-5	473780-76-6	473780-77-7
473780-81-3	473780-82-4	473780-84-6		

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

IT	474756-12-2	474756-13-3	474756-15-5	474756-17-7	474756-18-8
	474756-19-9	474756-20-2	474756-22-4	474756-26-8	474756-27-9
	474756-28-0	474756-32-6	474756-33-7	474756-37-1	474756-42-8
	474756-46-2	474756-49-5	474756-50-8	474756-53-1	474756-59-7
	474756-66-6	474756-69-9	474756-73-5	474756-74-6	474756-86-0
	474756-89-3	474756-90-6	474756-93-9	474756-95-1	474756-96-2
	474756-97-3	474756-99-5	474757-00-1	474757-01-2	474757-03-4
	474757-04-5	474757-05-6	474757-07-8	474757-08-9	474757-09-0
	474757-11-4	474757-12-5	474757-13-6	474757-14-7	474757-19-2
	474757-22-7	474757-23-8	474757-25-0	474757-27-2	474757-32-9

474757-35-2	474757-40-9	474757-48-7	474757-51-2	474757-53-4
474757-60-3	474757-61-4	474757-71-6	474757-72-7	474757-76-1
474757-78-3	474757-79-4	474757-81-8	474757-84-1	474757-89-6
474757-90-9	474757-92-1	474758-03-7	474758-06-0	474758-09-3
474758-10-6	474758-11-7	474758-12-8	474758-13-9	474758-17-3
474758-19-5	474758-21-9	474793-13-0	474793-14-1	474793-15-2
474793-16-3	474793-18-5	474793-20-9	474793-21-0	474793-22-1
474793-23-2	474793-25-4	474793-26-5	474793-27-6	474793-28-7
474793-29-8	474793-32-3	474793-36-7	474793-37-8	474793-38-9
474793-39-0	474793-40-3	474793-42-5	474793-43-6	474793-44-7
474793-45-8	474793-46-9	474793-47-0	474793-48-1	474793-49-2
474793-50-5	474793-52-7	474793-53-8	474793-54-9	474793-57-2
474793-58-3	474793-62-9	474793-63-0	474793-64-1	474793-68-5
474793-69-6	474793-70-9	474793-71-0	474793-72-1	474793-73-2
474793-76-5	474793-81-2	474793-82-3	474793-83-4	474793-84-5
474793-85-6	474793-88-9	474793-89-0	474793-90-3	474793-92-5
474793-94-7	474793-95-8	474793-96-9	474793-98-1	474794-00-8
474794-01-9	474794-03-1	474794-04-2	474794-05-3	474794-06-4
474794-08-6	474794-12-2	474794-13-3	474794-14-4	474794-16-6
474794-17-7	474794-18-8	474794-19-9	474794-20-2	
474794-22-4	474794-34-8	474794-38-2	474794-43-9	474794-45-1
474794-57-5	474794-75-7	474794-81-5	474794-83-7	474794-89-3
474794-90-6	474794-91-7	474794-92-8	474794-94-0	474794-99-5
474795-00-1	474795-01-2	474795-02-3	474795-03-4	474795-04-5
474795-05-6	474795-06-7	474795-07-8	474795-08-9	474795-11-4
474795-12-5	474795-13-6	474795-14-7	474795-15-8	474795-17-0
474795-19-2	474795-21-6	474795-24-9	474795-28-3	474795-29-4
474795-30-7	474795-31-8	474795-34-1	474795-35-2	474795-36-3
474795-38-5	474795-39-6	474795-43-2	474795-47-6	474795-51-2
474795-52-3	474795-53-4	474795-56-7	474795-60-3	474795-61-4
474795-62-5	474795-63-6	474795-67-0	474795-68-1	474795-70-5
474795-71-6	474795-72-7	474795-76-1	474795-77-2	474795-78-3
474795-81-8	474795-82-9	474795-85-2	474795-93-2	474795-95-4
474795-98-7	474796-00-4	474796-01-5	474796-02-6	474796-03-7
474796-04-8	474796-05-9	474796-06-0	474796-07-1	474796-08-2
474796-09-3	474796-10-6	474796-11-7	474796-12-8	474796-13-9
474796-14-0	474796-15-1	474796-17-3		

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

IT	474796-19-5	474796-20-8	474796-21-9	474796-22-0	474796-23-1
	474796-25-3	474796-26-4	474796-29-7	474796-30-0	474796-32-2
	474796-33-3	474796-35-5	474796-36-6	474796-38-8	474796-42-4
	474796-53-7	474796-56-0	474796-64-0	474796-66-2	474796-70-8
	474796-72-0	474796-74-2	474796-76-4	474796-77-5	474796-78-6
	474796-80-0	474796-81-1	474796-84-4	474796-88-8	474796-90-2
	474796-91-3	474796-97-9	474796-99-1	474797-01-8	474797-02-9
	474797-03-0	474797-04-1	474797-07-4	474797-08-5	474797-10-9
	474797-12-1	474797-17-6	474797-22-3	474797-23-4	474797-28-9
	474797-29-0	474797-30-3	474797-32-5	474797-33-6	474797-34-7
	474797-40-5	474797-44-9	474797-45-0	474797-47-2	474797-52-9
	474797-53-0	474797-54-1	474797-56-3	474797-58-5	474797-59-6
	474797-61-0	474797-64-3	474797-66-5	474797-67-6	474797-68-7
	474797-69-8	474797-70-1	474797-71-2	474797-72-3	474797-73-4
	474833-28-8	474833-29-9	474833-30-2	474833-31-3	474833-32-4
	474833-33-5	474833-34-6	474833-35-7	474833-36-8	474833-37-9
	474833-38-0	474833-39-1	474833-40-4	474833-41-5	474833-42-6
	474833-43-7	474833-44-8	474833-45-9	474833-46-0	474833-47-1

474833-48-2	474833-49-3	474833-50-6	474833-53-9	474833-54-0
474833-55-1	474833-56-2	474833-57-3	474833-58-4	474833-59-5
474833-60-8	474833-61-9	474833-62-0	474833-63-1	474833-64-2
474833-65-3	474833-66-4	474833-67-5	474833-68-6	474833-69-7
474833-70-0	474833-71-1	474833-72-2	474833-73-3	474833-74-4
474833-75-5	474833-76-6	474833-77-7	474833-78-8	474833-79-9
474833-80-2	474833-81-3	474833-82-4	474833-83-5	474833-84-6
474833-85-7	474833-86-8	474833-87-9	474833-88-0	474833-89-1
474833-90-4	474833-91-5	474833-92-6	474833-93-7	474833-94-8
474833-95-9	474833-96-0	474833-97-1	474833-98-2	474833-99-3
474834-00-9	474834-01-0	474834-02-1	474834-03-2	474834-04-3
474834-05-4	474834-06-5	474834-07-6	474834-08-7	474834-09-8
474834-10-1	474834-11-2	474834-12-3	474834-13-4	474834-14-5
474834-15-6	474834-16-7	474834-17-8	474834-18-9	474834-19-0
474834-20-3	474834-21-4	474834-22-5	474834-23-6	474834-24-7
474834-26-9	474834-30-5	474834-31-6	474834-32-7	474834-33-8
474834-34-9	474834-35-0	474834-36-1	474834-37-2	
474834-38-3	474834-39-4	474834-40-7	474834-41-8	474834-62-3
474834-70-3	474834-74-7	474834-98-5	474835-00-2	474835-01-3
474835-02-4	474835-03-5	474835-04-6	474835-05-7	474835-06-8
474835-07-9	474835-08-0	474835-09-1	474835-10-4	474835-11-5
474835-12-6	474835-13-7	474835-14-8	474835-15-9	474835-16-0
474835-17-1	474835-18-2	474835-19-3	474835-20-6	474835-21-7
474835-22-8	474835-23-9	474835-24-0	474835-26-2	474835-28-4
474835-29-5	474835-33-1	474835-35-3	474835-36-4	474835-39-7
474835-40-0	474835-41-1	474835-43-3	474835-76-2	474835-82-0
474835-88-6	474835-90-0	474835-95-5	474835-96-6	474836-04-9
474836-10-7	474836-12-9	474836-25-4	474836-40-3	474836-55-0
474836-57-2	474836-58-3	474836-61-8		

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

IT **473780-32-4 474794-20-2 474834-36-1**

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)


(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

RN 473780-32-4 CAPLUS


CN L-Arginine, L-cysteinyl-L-leucyl-L-alanyl-L-cysteinyl-L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 474794-20-2 CAPLUS


CN L-Arginine, L-cysteinyl-L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-lysyl-L-arginyl-L-cysteinyl-L-methionyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A





RN 474834-36-1 CAPLUS

CN L-Histidine, L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-lysyl-L-arginyl-L-cysteinyl-L-methionyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





L4 ANSWER 14 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:857449 CAPLUS

DOCUMENT NUMBER: 137:380978

TITLE: Human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers

INVENTOR(S): Jakobovits, Aya; Challita-Eid, Pia M.; Faris, Mary; Ge, Wangmao; Hubert, Rene S.; Morrison, Karen; Morrison, Robert Kendall; Raitano, Arthur B.

PATENT ASSIGNEE(S): Agensys, Inc., USA

SOURCE: PCT Int. Appl., 1021 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 30

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083921	A2	20021024	WO 2002-XH11654	20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2002083921	A2	20021024	WO 2002-US11654	20020410
WO 2002083921	C1	20051215		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,				

UA, UG, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 2005227253	A1	20051013	US 2004-990137	20041115
US 2006018917	A1	20060126	US 2004-989767	20041115
US 2005214211	A1	20050929	US 2005-73349	20050303
PRIORITY APPLN. INFO.:			US 2001-282739P	P 20010410
			US 2001-283112P	P 20010410
			US 2001-286630P	P 20010425
			WO 2002-US11654	A 20020410
			US 2000-227098P	P 20000822
			US 2001-300373P	P 20010622
			US 2001-935430	A1 20010822
			US 2002-120835	A3 20020409

ED Entered STN: 12 Nov 2002

AB Eighteen genes and their resp. encoded proteins, and variants thereof, are described wherein the gene exhibits restricted expression in normal adult tissue and is overexpressed in various cancers. Suppression subtractive hybridization (SSH) is used to identify cDNAs corresponding to genes that are differentially expressed in cancer; PCR amplification, cloning, and sequencing of gene fragments from SSH yield the full-length cDNAs. Consequently, the gene products provide diagnostic, prognostic, prophylactic, and/or therapeutic targets for cancer. The genes or fragment thereof, their encoded proteins, or variants or fragments thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with the gene products can be used in active or passive immunization. [This abstract record is one of 16 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IC ICM C12Q

CC 3-3 (Biochemical Genetics)

Section cross-reference(s): 1, 6, 9, 14

IT	473318-90-0	473318-93-3	473318-94-4	473318-95-5	473318-96-6
	473318-97-7	473319-00-5	473319-01-6	473319-02-7	473319-03-8
	473319-05-0	473319-11-8	473319-12-9	473319-13-0	
	473319-14-1	473319-16-3	473319-18-5	473319-19-6	473319-20-9
	473319-21-0	473319-22-1	473319-23-2	473319-24-3	473319-25-4
	473319-26-5	473319-27-6	473319-28-7	473319-29-8	473319-30-1
	473319-31-2	473319-32-3	473319-33-4	473319-34-5	473319-35-6
	473319-36-7	473319-37-8	473319-38-9	473319-39-0	473319-40-3
	473319-41-4	473319-42-5	473319-43-6	473319-44-7	473319-45-8
	473319-46-9	473319-47-0	473319-48-1	473319-49-2	473319-50-5
	473319-51-6	473319-52-7	473319-53-8	473319-54-9	473319-55-0
	473319-56-1	473319-57-2	473319-59-4	473319-61-8	473319-62-9
	473319-63-0	473319-64-1	473319-65-2	473319-66-3	473319-67-4
	473319-68-5	473319-69-6	473319-70-9	473319-71-0	473319-72-1
	473319-73-2	473319-74-3	473319-75-4	473319-76-5	473319-78-7
	473319-79-8	473319-80-1	473319-81-2	473319-82-3	473319-83-4
	473319-84-5	473319-85-6	473319-86-7	473319-87-8	473319-88-9
	473319-89-0	473319-90-3	473319-91-4	473319-92-5	473319-93-6
	473319-94-7	473319-95-8	473319-96-9	473319-97-0	473319-98-1
	473319-99-2	473320-00-2	473320-01-3	473320-02-4	473320-03-5
	473320-04-6	473320-06-8	473320-07-9	473320-08-0	473320-09-1
	473320-10-4	473320-11-5	473320-12-6	473320-14-8	473320-16-0
	473320-17-1	473320-18-2	473320-19-3	473320-22-8	473320-23-9
	473320-25-1	473320-27-3	473320-28-4	473320-31-9	473320-33-1
	473320-34-2	473320-35-3	473320-37-5	473320-39-7	473320-40-0
	473320-41-1	473320-42-2	473320-44-4	473320-45-5	473320-47-7

473320-48-8	473320-52-4	473320-53-5	473320-54-6	473320-58-0
473320-62-6	473320-66-0	473320-67-1	473320-71-7	473320-73-9
473320-74-0	473320-76-2	473320-77-3	473320-82-0	473320-84-2
473320-86-4	473320-88-6	473320-89-7	473320-90-0	473320-91-1
473320-92-2	473320-93-3	473320-95-5	473320-97-7	473320-99-9
473321-00-5	473321-06-1	473321-07-2	473321-08-3	473321-09-4
473321-11-8	473321-16-3	473321-19-6	473321-20-9	473321-21-0
473321-22-1	473321-23-2	473321-25-4	473321-27-6	473321-28-7
473321-29-8	473321-32-3	473321-33-4	473321-35-6	473321-36-7
473321-38-9	473321-39-0	473321-42-5	473321-43-6	473321-44-7
473321-46-9	473321-47-0	473321-48-1	473321-49-2	473321-51-6
473321-52-7	473321-53-8	473321-58-3	473321-59-4	473321-61-8
473321-63-0	473321-65-2	473321-66-3	473321-67-4	473321-69-6
473321-70-9	473321-71-0	473321-72-1	473321-74-3	473321-75-4
473321-76-5	473321-78-7	473321-82-3	473321-85-6	473321-87-8
473321-88-9	473321-89-0	473321-90-3	473321-91-4	473321-92-5
473321-93-6	473321-94-7	473321-95-8	473321-96-9	473321-97-0
473321-98-1	473322-02-0	473322-05-3	473322-06-4	473322-08-6
473322-10-0	473322-11-1	473322-12-2	473322-13-3	473322-14-4
473322-15-5	473322-17-7	473322-19-9	473322-20-2	473322-21-3
473322-22-4	473322-24-6	473322-25-7		

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

IT	474290-42-1	474290-46-5	474290-55-6	474290-57-8	474290-71-6
	474290-82-9	474290-84-1	474290-96-5	474290-97-6	474290-98-7
	474291-12-8	474291-16-2	474291-17-3	474291-21-9	474291-26-4
	474291-29-7	474291-32-2	474291-42-4	474291-43-5	474291-49-1
	474291-63-9	474291-72-0	474291-75-3	474291-82-2	474291-93-5
	474292-00-7	474292-01-8	474292-61-0	474292-62-1	474292-63-2
	474292-65-4	474292-66-5	474292-67-6	474292-68-7	474292-72-3
	474292-74-5	474292-75-6	474292-77-8	474292-80-3	474292-83-6
	474292-85-8	474292-90-5	474292-94-9	474292-97-2	474293-04-4
	474293-14-6	474293-23-7	474293-29-3	474293-33-9	474293-39-5
	474293-40-8	474293-48-6	474293-51-1	474293-53-3	474293-54-4
	474293-55-5	474293-56-6	474293-57-7	474293-58-8	474293-60-2
	474293-61-3	474293-62-4	474293-64-6	474293-65-7	474293-67-9
	474293-69-1	474293-71-5	474293-74-8	474293-77-1	474293-78-2
	474293-80-6	474293-83-9	474293-85-1	474293-86-2	474293-88-4
	474293-90-8	474293-93-1	474294-00-3	474294-03-6	474294-09-2
	474294-14-9	474294-15-0	474294-18-3	474294-26-3	474294-27-4
	474294-28-5	474294-30-9	474294-31-0	474294-32-1	474294-33-2
	474294-35-4	474294-37-6	474294-38-7	474294-39-8	474294-42-3
	474294-43-4	474294-44-5	474294-49-0	474294-50-3	474294-57-0
	474294-58-1	474294-62-7	474294-68-3	474294-76-3	474294-85-4
	474294-86-5	474294-87-6	474294-92-3	474294-94-5	474294-95-6
	474294-96-7	474294-97-8	474295-00-6	474295-01-7	474295-02-8
	474295-05-1	474295-06-2	474295-07-3	474295-08-4	474295-13-1
	474295-17-5	474295-18-6	474295-25-5	474295-28-8	474295-30-2
	474295-35-7	474295-37-9	474295-43-7	474295-44-8	474295-47-1
	474295-50-6	474769-05-6	474769-28-3	474769-52-3	474770-21-3
	474770-27-9	474770-46-2	474770-53-1	474770-58-6	474770-63-3
	474770-65-5	474770-72-4	474770-77-9	474770-79-1	474770-81-5
	474770-84-8	474770-86-0	474770-90-6	474770-92-8	474770-96-2
	474770-98-4	474771-00-1	474771-02-3	474771-05-6	474771-07-8
	474771-08-9	474771-17-0	474771-20-5	474771-23-8	474771-25-0
	474771-35-2	474771-38-5	474771-40-9	474771-47-6	474771-49-8
	474771-53-4	474771-56-7	474771-63-6	474771-82-9	474771-91-0

474771-93-2	474771-96-5	474771-99-8	474772-04-8	474772-10-6
474772-19-5	474772-21-9	474772-25-3	474772-30-0	474772-32-2
474772-35-5	474772-37-7	474772-39-9	474772-41-3	474772-43-5
474772-47-9	474772-52-6	474772-56-0	474772-58-2	474772-61-7
474772-63-9	474772-67-3	474772-77-5	474772-79-7	474772-80-0
474772-81-1	474772-82-2	474772-86-6	474772-87-7	474772-89-9
474772-92-4	474772-96-8	474772-98-0	474772-99-1	474773-00-7
474773-02-9	474773-03-0	474773-06-3	474773-07-4	474773-10-9
474773-12-1	474773-15-4	474773-21-2	474774-12-4	474774-13-5
474774-14-6	474774-16-8	474774-19-1	474774-23-7	474774-24-8
474774-25-9	474774-27-1	474774-28-2	474774-81-7	474774-84-0
474774-85-1	474774-86-2	474774-87-3	474774-90-8	474774-91-9
474774-93-1	474774-96-4			

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

IT **473319-12-9 474773-10-9**

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)


(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)


RN 473319-12-9 CAPLUS

CN L-Arginine, L-leucyl-L-alanyl-L-cysteinyl-L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 474773-10-9 CAPLUS

CN L-Arginine, L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-lysyl-L-arginyl-L-cysteinyl-L-methionyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B



L4 ANSWER 15 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:857448 CAPLUS
 DOCUMENT NUMBER: 137:380977
 TITLE: Human nucleic acids and corresponding proteins useful
 in the detection and treatment of various cancers
 INVENTOR(S): Jakobovits, Aya; Challita-Eid, Pia M.; Faris, Mary;
 Ge, Wangmao; Hubert, Rene S.; Morrison, Karen;
 Morrison, Robert Kendall; Raitano, Arthur B.
 PATENT ASSIGNEE(S): Agensys, Inc., USA
 SOURCE: PCT Int. Appl., 1021 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 30
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083921	A2	20021024	WO 2002-XG11654	20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2002083921	A2	20021024	WO 2002-US11654	20020410
WO 2002083921	C1	20051215		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,				

UA, UG, UZ, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG,
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 2005227253	A1	20051013	US 2004-990137	20041115
US 2006018917	A1	20060126	US 2004-989767	20041115
US 2005214211	A1	20050929	US 2005-73349	20050303

PRIORITY APPLN. INFO.:

US 2001-282739P	P	20010410
US 2001-283112P	P	20010410
US 2001-286630P	P	20010425
WO 2002-US11654	A	20020410
US 2000-227098P	P	20000822
US 2001-300373P	P	20010622
US 2001-935430	A1	20010822
US 2002-120835	A3	20020409

ED Entered STN: 12 Nov 2002

AB Eighteen genes and their resp. encoded proteins, and variants thereof, are described wherein the gene exhibits restricted expression in normal adult tissue and is overexpressed in various cancers. Suppression subtractive hybridization (SSH) is used to identify cDNAs corresponding to genes that are differentially expressed in cancer; PCR amplification, cloning, and sequencing of gene fragments from SSH yield the full-length cDNAs. Consequently, the gene products provide diagnostic, prognostic, prophylactic, and/or therapeutic targets for cancer. The genes or fragment thereof, their encoded proteins, or variants or fragments thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with the gene products can be used in active or passive immunization. [This abstract record is one of 16 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IC ICM C12Q

CC 3-3 (Biochemical Genetics)

Section cross-reference(s): 1, 6, 9, 14

IT 99026-80-9	144722-25-8	168136-63-8	473775-84-7	473775-85-8
473775-86-9	473775-87-0	473775-88-1	473775-90-5	473775-91-6
473775-92-7	473775-93-8	473775-94-9	473775-95-0	473775-96-1
473775-97-2	473775-98-3	473775-99-4	473776-01-1	473776-02-2
473776-03-3	473776-04-4	473776-05-5	473776-07-7	473776-08-8
473776-11-3	473776-12-4	473776-14-6	473776-15-7	473776-16-8
473776-17-9	473776-18-0	473776-19-1	473776-20-4	473776-23-7
473776-24-8	473776-25-9	473776-26-0	473776-28-2	473776-29-3
473776-32-8	473776-33-9	473776-34-0	473776-35-1	473776-36-2
473776-37-3	473776-38-4	473776-39-5	473776-42-0	473776-43-1
473776-44-2	473776-45-3	473776-47-5	473776-48-6	473776-49-7
473776-50-0	473776-51-1	473776-52-2	473776-53-3	473776-56-6
473776-58-8	473776-59-9	473776-60-2	473776-61-3	473776-63-5
473776-65-7	473776-68-0	473776-70-4	473776-71-5	473776-72-6
473776-79-3	473776-80-6	473776-82-8	473776-84-0	473776-85-1
473776-86-2	473776-88-4	473776-92-0	473776-94-2	473777-00-3
473777-06-9	473777-08-1	473777-10-5	473777-12-7	473777-13-8
473777-16-1	473777-17-2	473777-20-7	473777-22-9	473777-23-0
473777-24-1	473777-25-2	473777-26-3	473777-27-4	473777-28-5
473777-29-6	473777-30-9	473777-33-2	473777-36-5	473777-37-6
473777-38-7	473777-39-8	473777-41-2	473777-44-5	473777-47-8
473777-48-9	473777-49-0	473777-52-5	473777-53-6	473777-54-7
473777-56-9	473777-57-0	473777-65-0	473777-66-1	473777-67-2
473777-68-3	473777-69-4	473777-70-7	473777-71-8	473777-73-0
473777-75-2	473777-76-3	473777-77-4	473777-78-5	473777-79-6
473777-80-9	473777-81-0	473777-82-1	473777-83-2	473777-84-3

473777-85-4	473777-86-5	473777-87-6	473777-88-7	473777-90-1
473777-92-3	473777-93-4	473777-99-0	473778-00-6	473778-04-0
473778-06-2	473778-10-8	473778-25-5	473778-26-6	473778-28-8
473778-36-8	473778-37-9	473778-38-0	473778-41-5	473778-42-6
473778-46-0	473778-47-1	473778-48-2	473778-72-2	473778-78-8
473778-81-3	473778-84-6	473778-87-9	473778-96-0	473778-97-1
473778-98-2	473779-00-9	473779-01-0	473779-04-3	473779-06-5
473779-08-7	473779-09-8	473779-11-2	473779-14-5	473779-15-6
473779-16-7	473779-18-9	473779-22-5	473779-23-6	473779-24-7
473779-26-9	473779-27-0	473779-29-2	473779-31-6	473779-42-9
473779-45-2	473779-46-3	473779-47-4	473779-48-5	473779-67-8
473779-69-0	473779-70-3	473779-71-4	473779-75-8	473779-76-9
473779-77-0	473779-79-2	473779-85-0	473779-86-1	473779-89-4
473779-93-0	473779-94-1	473779-95-2	473779-97-4	473779-98-5
473780-00-6	473780-03-9	473780-04-0	473780-05-1	473780-06-2
473780-07-3	473780-08-4	473780-09-5	473780-10-8	473780-11-9
473780-12-0	473780-14-2	473780-15-3	473780-16-4	473780-17-5
473780-19-7	473780-20-0	473780-22-2	473780-23-3	473780-24-4
473780-26-6	473780-27-7	473780-30-2	473780-31-3	473780-32-4
473780-33-5	473780-34-6	473780-36-8	473780-39-1	473780-40-4
473780-43-7	473780-44-8			

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

IT 474757-66-9	474757-69-2	474757-70-5	474757-72-7	474757-73-8
474757-76-1	474757-78-3	474757-79-4	474757-81-8	474757-82-9
474757-84-1	474757-86-3	474757-89-6	474757-90-9	474757-92-1
474758-03-7	474758-04-8	474758-07-1	474758-08-2	474758-09-3
474758-10-6	474758-14-0	474758-18-4	474758-19-5	474758-23-1
474793-13-0	474793-14-1	474793-15-2	474793-16-3	474793-17-4
474793-18-5	474793-19-6	474793-20-9	474793-21-0	474793-22-1
474793-23-2	474793-24-3	474793-25-4	474793-26-5	474793-27-6
474793-28-7	474793-29-8	474793-30-1	474793-31-2	474793-32-3
474793-33-4	474793-34-5	474793-35-6	474793-36-7	474793-37-8
474793-38-9	474793-39-0	474793-40-3	474793-42-5	474793-43-6
474793-44-7	474793-45-8	474793-46-9	474793-47-0	474793-48-1
474793-49-2	474793-50-5	474793-51-6	474793-52-7	474793-53-8
474793-54-9	474793-55-0	474793-56-1	474793-57-2	474793-58-3
474793-59-4	474793-60-7	474793-61-8	474793-62-9	474793-63-0
474793-64-1	474793-65-2	474793-66-3	474793-67-4	474793-68-5
474793-69-6	474793-70-9	474793-71-0	474793-72-1	474793-73-2
474793-74-3	474793-75-4	474793-76-5	474793-77-6	474793-78-7
474793-79-8	474793-80-1	474793-81-2	474793-82-3	474793-83-4
474793-84-5	474793-85-6	474793-86-7	474793-88-9	474793-89-0
474793-90-3	474793-91-4	474793-92-5	474793-93-6	474793-94-7
474793-95-8	474793-96-9	474793-97-0	474793-98-1	474794-00-8
474794-01-9	474794-02-0	474794-03-1	474794-04-2	474794-05-3
474794-06-4	474794-07-5	474794-08-6	474794-09-7	474794-10-0
474794-11-1	474794-12-2	474794-13-3	474794-14-4	474794-15-5
474794-16-6	474794-17-7	474794-18-8	474794-19-9	474794-20-2
474794-21-3	474794-22-4	474794-23-5	474794-24-6	474794-25-7
474794-26-8	474794-27-9	474794-28-0	474794-29-1	474794-30-4
474794-32-6	474794-33-7	474794-34-8	474794-35-9	474794-38-2
474794-41-7	474794-43-9	474794-45-1	474794-49-5	474794-57-5
474794-69-9	474794-75-7	474794-77-9	474794-79-1	474794-80-4
474794-81-5	474794-82-6	474794-83-7	474794-84-8	474794-85-9
474794-86-0	474794-87-1	474794-89-3	474794-90-6	474794-91-7
474794-92-8	474794-93-9	474794-94-0	474794-95-1	474794-96-2

474794-97-3	474794-98-4	474794-99-5	474795-00-1	474795-01-2
474795-02-3	474795-03-4	474795-04-5	474795-05-6	474795-06-7
474795-07-8	474795-08-9	474795-09-0	474795-10-3	474795-11-4
474795-12-5	474795-13-6	474795-14-7	474795-15-8	474795-16-9
474795-17-0	474795-18-1	474795-19-2	474795-20-5	474795-21-6
474795-22-7	474795-23-8	474795-24-9	474795-25-0	474795-26-1
474795-27-2	474795-28-3	474795-29-4	474795-30-7	474795-31-8
474795-32-9	474795-34-1	474795-35-2	474795-36-3	474795-37-4
474795-38-5	474795-39-6	474795-41-0	474795-42-1	474795-43-2
474795-44-3	474795-45-4	474795-46-5	474795-47-6	474795-48-7
474795-49-8	474795-50-1	474795-51-2	474795-52-3	474795-53-4
474795-54-5	474795-56-7	474795-60-3	474795-61-4	474795-62-5
474795-63-6	474795-64-7			

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

IT 473780-32-4 474794-20-2

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)


(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

RN 473780-32-4 CAPLUS


CN L-Arginine, L-cysteinyl-L-leucyl-L-alanyl-L-cysteinyl-L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 474794-20-2 CAPLUS


CN L-Arginine, L-cysteinyl-L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-lysyl-L-arginyl-L-cysteinyl-L-methionyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A



L4 ANSWER 16 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:857447 CAPLUS
 DOCUMENT NUMBER: 137:380976
 TITLE: Human nucleic acids and corresponding proteins useful
 in the detection and treatment of various cancers
 INVENTOR(S): Jakobovits, Aya; Challita-Eid, Pia M.; Faris, Mary;
 Ge, Wangmao; Hubert, Rene S.; Morrison, Karen;
 Morrison, Robert Kendall; Raitano, Arthur B.
 PATENT ASSIGNEE(S): Agensys, Inc., USA
 SOURCE: PCT Int. Appl., 1021 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 30
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083921	A2	20021024	WO 2002-XF11654	20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, UZ, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 WO 2002083921 A2 20021024 WO 2002-US11654 20020410
 WO 2002083921 C1 20051215
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, UZ, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG,
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 US 2005227253 A1 20051013 US 2004-990137 20041115
 US 2006018917 A1 20060126 US 2004-989767 20041115
 US 2005214211 A1 20050929 US 2005-73349 20050303
 PRIORITY APPLN. INFO.:
 US 2001-282739P P 20010410
 US 2001-283112P P 20010410
 US 2001-286630P P 20010425
 WO 2002-US11654 A 20020410
 US 2000-227098P P 20000822
 US 2001-300373P P 20010622
 US 2001-935430 A1 20010822
 US 2002-120835 A3 20020409
 ED Entered STN: 12 Nov 2002
 AB Eighteen genes and their resp. encoded proteins, and variants thereof, are described wherein the gene exhibits restricted expression in normal adult tissue and is overexpressed in various cancers. Suppression subtractive hybridization (SSH) is used to identify cDNAsd corresponding to genes that are differentially expressed in cancer; PCR amplification, cloning, and sequencing of gene fragments from SSH yield the full-length cDNAs. Consequently, the gene products provide diagnostic, prognostic, prophylactic, and/or therapeutic targets for cancer. The genes or fragment thereof, their encoded proteins, or variants or fragments thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with the gene products can be used in active or passive immunization. [This abstract record is one of 16 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].
 IC ICM C12Q
 CC 3-3 (Biochemical Genetics)
 Section cross-reference(s): 1, 6, 9, 14
 IT 473318-93-3 473318-94-4 473318-95-5 473318-96-6 473318-97-7
 473319-00-5 473319-01-6 473319-02-7 473319-03-8 473319-05-0
 473319-11-8 473319-12-9 473319-13-0 473319-14-1
 473319-16-3 473319-18-5 473319-19-6 473319-20-9 473319-21-0
 473319-22-1 473319-23-2 473319-24-3 473319-25-4 473319-26-5
 473319-27-6 473319-28-7 473319-29-8 473319-30-1 473319-31-2
 473319-32-3 473319-33-4 473319-34-5 473319-35-6 473319-36-7
 473319-37-8 473319-38-9 473319-39-0 473319-40-3 473319-41-4
 473319-42-5 473319-43-6 473319-44-7 473319-45-8 473319-46-9
 473319-47-0 473319-48-1 473319-49-2 473319-50-5 473319-51-6
 473319-52-7 473319-53-8 473319-54-9 473319-55-0 473319-56-1
 473319-57-2 473319-59-4 473319-61-8 473319-62-9 473319-63-0

473319-64-1	473319-65-2	473319-66-3	473319-67-4	473319-68-5
473319-69-6	473319-70-9	473319-71-0	473319-72-1	473319-73-2
473319-74-3	473319-75-4	473319-76-5	473319-78-7	473319-79-8
473319-80-1	473319-81-2	473319-82-3	473319-83-4	473319-84-5
473319-85-6	473319-86-7	473319-87-8	473319-88-9	473319-89-0
473319-90-3	473319-91-4	473319-92-5	473319-93-6	473319-94-7
473319-95-8	473319-96-9	473319-97-0	473319-98-1	473319-99-2
473320-00-2	473320-01-3	473320-02-4	473320-03-5	473320-04-6
473320-06-8	473320-07-9	473320-08-0	473320-09-1	473320-10-4
473320-11-5	473320-12-6	473320-14-8	473320-16-0	473320-17-1
473320-18-2	473320-19-3	473320-21-7	473320-22-8	473320-23-9
473320-25-1	473320-27-3	473320-28-4	473320-31-9	473320-33-1
473320-34-2	473320-35-3	473320-36-4	473320-37-5	473320-38-6
473320-39-7	473320-40-0	473320-41-1	473320-44-4	473320-47-7
473320-48-8	473320-52-4	473320-53-5	473320-54-6	473320-57-9
473320-58-0	473320-63-7	473320-66-0	473320-67-1	473320-69-3
473320-71-7	473320-72-8	473320-73-9	473320-74-0	473320-76-2
473320-82-0	473320-84-2	473320-85-3	473320-88-6	473320-89-7
473320-90-0	473320-91-1	473320-92-2	473320-93-3	473320-95-5
473320-97-7	473320-99-9	473321-00-5	473321-04-9	473321-06-1
473321-07-2	473321-08-3	473321-09-4	473321-11-8	473321-14-1
473321-16-3	473321-17-4	473321-19-6	473321-20-9	473321-21-0
473321-22-1	473321-23-2	473321-25-4	473321-27-6	473321-28-7
473321-31-2	473321-32-3	473321-33-4	473321-34-5	473321-35-6
473321-36-7	473321-39-0	473321-41-4	473321-42-5	473321-43-6
473321-44-7	473321-46-9	473321-47-0	473321-48-1	473321-50-5
473321-51-6	473321-52-7	473321-53-8	473321-57-2	473321-58-3
473321-59-4	473321-61-8	473321-62-9	473321-63-0	473321-64-1
473321-66-3	473321-67-4	473321-69-6	473321-70-9	473321-71-0
473321-72-1	473321-74-3	473321-75-4	473321-76-5	473321-78-7
473321-80-1	473321-82-3	473321-84-5	473321-85-6	473321-86-7
473321-87-8	473321-88-9	473321-89-0	473321-90-3	473321-91-4
473321-92-5	473321-93-6	473321-94-7	473321-95-8	473321-96-9
473321-98-1	473322-01-9	473322-02-0	473322-05-3	473322-06-4
473322-07-5	473322-08-6	473322-10-0		

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

IT	474294-85-4	474294-92-3	474294-94-5	474294-95-6	474294-96-7
	474294-97-8	474295-00-6	474295-01-7	474295-02-8	474295-04-0
	474295-05-1	474295-06-2	474295-07-3	474295-08-4	474295-09-5
	474295-12-0	474295-13-1	474295-14-2	474295-17-5	474295-18-6
	474295-22-2	474295-24-4	474295-26-6	474295-31-3	474295-35-7
	474295-39-1	474295-43-7	474295-47-1	474769-05-6	474769-28-3
	474769-48-7	474769-52-3	474770-21-3	474770-27-9	474770-46-2
	474770-53-1	474770-58-6	474770-63-3	474770-65-5	474770-68-8
	474770-72-4	474770-77-9	474770-79-1	474770-81-5	474770-84-8
	474770-86-0	474770-90-6	474770-92-8	474770-94-0	474770-96-2
	474770-98-4	474771-00-1	474771-02-3	474771-05-6	474771-07-8
	474771-08-9	474771-15-8	474771-17-0	474771-20-5	474771-23-8
	474771-25-0	474771-27-2	474771-35-2	474771-38-5	474771-40-9
	474771-43-2	474771-45-4	474771-47-6	474771-49-8	474771-53-4
	474771-56-7	474771-61-4	474771-63-6	474771-66-9	474771-68-1
	474771-78-3	474771-80-7	474771-82-9	474771-85-2	474771-87-4
	474771-91-0	474771-93-2	474771-96-5	474771-99-8	474772-04-8
	474772-07-1	474772-10-6	474772-17-3	474772-19-5	474772-21-9
	474772-25-3	474772-30-0	474772-32-2	474772-35-5	474772-37-7
	474772-39-9	474772-41-3	474772-43-5	474772-47-9	474772-52-6

474772-56-0	474772-58-2	474772-59-3	474772-61-7	474772-63-9
474772-67-3	474772-74-2	474772-75-3	474772-76-4	474772-77-5
474772-78-6	474772-79-7	474772-80-0	474772-81-1	474772-82-2
474772-83-3	474772-84-4	474772-85-5	474772-86-6	474772-87-7
474772-88-8	474772-89-9	474772-90-2	474772-91-3	474772-92-4
474772-93-5	474772-94-6	474772-95-7	474772-96-8	474772-97-9
474772-98-0	474772-99-1	474773-00-7	474773-01-8	474773-02-9
474773-03-0	474773-06-3	474773-07-4	474773-10-9	
474773-12-1	474773-15-4	474773-21-2	474774-12-4	474774-13-5
474774-14-6	474774-16-8	474774-19-1	474774-22-6	474774-23-7
474774-24-8	474774-25-9	474774-27-1	474774-28-2	474774-29-3
474774-30-6	474774-31-7	474774-71-5	474774-74-8	474774-81-7
474774-83-9	474774-84-0	474774-85-1	474774-86-2	474774-87-3
474774-88-4	474774-89-5	474774-90-8	474774-91-9	474774-92-0
474774-93-1	474774-94-2	474774-95-3	474774-96-4	474774-97-5
474774-98-6	474774-99-7	474775-00-3	474775-01-4	474775-02-5
474775-03-6	474775-05-8	474775-11-6	474775-15-0	474775-17-2
474775-18-3	474775-19-4	474775-20-7	474775-21-8	474775-22-9
474775-23-0	474775-24-1	474775-25-2	474775-26-3	474775-27-4
474775-28-5	474775-29-6	474775-30-9	474775-33-2	474775-35-4
474775-37-6	474775-38-7	474775-39-8	474775-40-1	474775-41-2
474775-42-3	474775-43-4	474775-44-5	474775-45-6	474775-46-7
474775-47-8	474775-48-9	474775-49-0	474775-50-3	474775-51-4
474775-52-5	474775-53-6	474775-54-7	474775-55-8	474775-56-9
474775-57-0	474775-59-2	474775-60-5	474775-61-6	474775-62-7
474775-63-8	474775-64-9	474775-65-0	474775-66-1	474775-67-2
474775-68-3	474775-69-4	474775-70-7		

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

IT 473319-12-9 474773-10-9

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)


(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

RN 473319-12-9 CAPLUS


CN L-Arginine, L-leucyl-L-alanyl-L-cysteinyl-L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 474773-10-9 CAPLUS
 CN L-Arginine, L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-lysyl-L-arginyl-L-cysteiny-L-methionyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L4 ANSWER 17 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:857446 CAPLUS

DOCUMENT NUMBER: 137:380975

TITLE: Human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers

INVENTOR(S): Jakobovits, Aya; Challita-Eid, Pia M.; Faris, Mary;

Ge, Wangmao; Hubert, Rene S.; Morrison, Karen;
Morrison, Robert Kendall; Raitano, Arthur B.
PATENT ASSIGNEE(S): Agensys, Inc., USA
SOURCE: PCT Int. Appl., 1021 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 30
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083921	A2	20021024	WO 2002-XE11654	20020410
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2002083921	A2	20021024	WO 2002-US11654	20020410
WO 2002083921	C1	20051215		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
US 2005227253	A1	20051013	US 2004-990137	20041115
US 2006018917	A1	20060126	US 2004-989767	20041115
US 2005214211	A1	20050929	US 2005-73349	20050303
PRIORITY APPLN. INFO.:			US 2001-282739P	P 20010410
			US 2001-283112P	P 20010410
			US 2001-286630P	P 20010425
			WO 2002-US11654	A 20020410
			US 2000-227098P	P 20000822
			US 2001-300373P	P 20010622
			US 2001-935430	A1 20010822
			US 2002-120835	A3 20020409

ED Entered STN: 12 Nov 2002

AB Eighteen genes and their resp. encoded proteins, and variants thereof, are described wherein the gene exhibits restricted expression in normal adult tissue and is overexpressed in various cancers. Suppression subtractive hybridization (SSH) is used to identify cDNAs corresponding to genes that are differentially expressed in cancer; PCR amplification, cloning, and sequencing of gene fragments from SSH yield the full-length cDNAs. Consequently, the gene products provide diagnostic, prognostic, prophylactic, and/or therapeutic targets for cancer. The genes or fragment thereof, their encoded proteins, or variants or fragments thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with the gene products can be used in active or passive immunization. [This abstract record is one of 16 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IC ICM C12Q
 CC 3-3 (Biochemical Genetics)
 Section cross-reference(s): 1, 6, 9, 14
 IT 474747-13-2 474747-14-3 474747-15-4 474747-16-5 474747-17-6
 474747-18-7 474747-19-8 474747-20-1 474747-21-2 474747-22-3
 474747-23-4 474747-24-5 474747-25-6 474747-26-7 474747-27-8
 474747-28-9 474747-29-0 474747-30-3 474747-31-4 474747-32-5
 474747-33-6 474747-34-7 474747-35-8 474747-36-9 474747-37-0
 474747-38-1 474747-39-2 474747-40-5 474747-41-6 474747-42-7
 474747-43-8 474747-44-9 474747-45-0 474747-46-1 474747-47-2
 474747-48-3 474747-49-4 474747-50-7 474747-51-8 474747-52-9
 474747-53-0 474747-54-1 474747-58-5 474747-59-6 474747-60-9
 474747-61-0 474747-62-1 474747-63-2 474747-64-3 474747-65-4
 474747-66-5 474747-67-6 474747-68-7 474747-69-8 474747-70-1
 474747-71-2 474747-72-3 474747-73-4 474747-74-5 474747-75-6
 474747-76-7 474747-77-8 474747-78-9 474747-79-0 474747-80-3
 474747-81-4 474747-82-5 474747-83-6 474747-84-7 474747-85-8
 474747-86-9 474747-87-0 474747-88-1 474747-89-2 474747-90-5
 474747-91-6 474747-92-7 474747-93-8 474747-94-9 474747-95-0
 474747-96-1 474747-97-2 474747-98-3 474748-00-0 474748-01-1
 474748-02-2 474748-03-3 474748-04-4 474748-05-5 474748-07-7
 474748-09-9 474748-11-3 474748-13-5 474748-14-6 474748-16-8
 474748-18-0 474748-20-4 474748-22-6 474748-24-8 474748-26-0
 474748-27-1 474748-28-2 474748-29-3 474748-30-6 474748-31-7
 474748-32-8 474748-33-9 474748-34-0 474748-35-1 474748-36-2
 474748-37-3 474748-38-4 474748-39-5 474748-40-8 474748-41-9
 474748-42-0 474748-43-1 474748-44-2 474748-45-3 474748-46-4
 474748-47-5 474748-48-6 474748-49-7 474748-50-0 474748-51-1
 474748-52-2 474748-53-3 474748-54-4 474748-55-5 474748-56-6
 474748-57-7 474748-58-8 474748-59-9 474748-60-2 474748-61-3
 474748-62-4 474748-63-5 474748-64-6 474748-65-7 474748-66-8
 474748-67-9 474748-68-0 474748-69-1 474748-70-4 474748-71-5
 474748-72-6 474748-73-7 474748-74-8 474748-75-9 474748-76-0
 474748-77-1 474748-78-2 474748-79-3 474748-80-6 474748-81-7
 474748-82-8 474748-83-9 474748-84-0 474748-85-1 474748-86-2
 474748-87-3 474748-88-4 474748-89-5 474748-90-8 474748-91-9
 474748-92-0 474748-93-1 474748-94-2 474748-95-3 474748-96-4
 474748-97-5 474748-98-6 474748-99-7 474749-00-3 474749-01-4
 474749-02-5 474749-03-6 474749-04-7 474749-05-8 474749-06-9
 474749-07-0 474749-08-1 474749-09-2 474749-10-5 474749-11-6
474749-12-7 474749-13-8 474749-14-9 474749-15-0
 474749-16-1 474749-17-2 474749-18-3 474749-19-4 474749-20-7
 474749-21-8 474749-22-9 474749-23-0 474749-24-1 474749-25-2
 474749-26-3 474749-27-4 474749-28-5 474749-29-6 474749-30-9
 474749-31-0 474749-32-1 474749-33-2 474749-34-3 474749-35-4
 474749-36-5 474749-37-6 474749-38-7 474749-39-8 474749-40-1
 474749-41-2 474749-42-3 474749-43-4 474749-44-5 474749-45-6
 474749-46-7 474749-47-8 474749-48-9 474749-49-0 474749-50-3
 474749-51-4 474749-52-5 474749-53-6 474749-54-7 474749-55-8
 474749-56-9 474749-57-0 474749-58-1
 RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)
 IT **474749-12-7**
 RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (peptide epitope; human nucleic acids and corresponding proteins useful


in the detection and treatment of various cancers)

RN 474749-12-7 CAPLUS


CN L-Cysteine, L-leucyl-L-alanyl-L-cysteinyl-L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-lysyl-L-arginyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





L4 ANSWER 18 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:857443 CAPLUS
 DOCUMENT NUMBER: 137:321378
 TITLE: Human nucleic acids and corresponding proteins useful
 in the detection and treatment of various cancers
 INVENTOR(S): Jakobovits, Aya; Challita-Eid, Pia M.; Faris, Mary;
 Ge, Wangmao; Hubert, Rene S.; Morrison, Karen;
 Morrison, Robert Kendall; Raitano, Arthur B.
 PATENT ASSIGNEE(S): Agensys, Inc., USA
 SOURCE: PCT Int. Appl., 1021 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 30
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083921	A2	20021024	WO 2002-XC11654	20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2002083921	A2	20021024	WO 2002-US11654	20020410
WO 2002083921	C1	20051215		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2005227253	A1	20051013	US 2004-990137	20041115
US 2006018917	A1	20060126	US 2004-989767	20041115
US 2005214211	A1	20050929	US 2005-73349	20050303
PRIORITY APPLN. INFO.:			US 2001-282739P	P 20010410
			US 2001-283112P	P 20010410
			US 2001-286630P	P 20010425
			WO 2002-US11654	A 20020410
			US 2000-227098P	P 20000822
			US 2001-300373P	P 20010622
			US 2001-935430	A1 20010822

ED Entered STN: 12 Nov 2002

AB Eighteen genes and their resp. encoded proteins, and variants thereof, are described wherein the gene exhibits restricted expression in normal adult tissue and is overexpressed in various cancers. Suppression subtractive hybridization (SSH) is used to identify cDNAs corresponding to genes that are differentially expressed in cancer; PCR amplification, cloning, and sequencing of gene fragments from SSH yield the full-length cDNAs. Consequently, the gene products provide diagnostic, prognostic, prophylactic, and/or therapeutic targets for cancer. The genes or fragment thereof, their encoded proteins, or variants or fragments thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with the gene products can be used in active or passive immunization. [This abstract record is one of 16 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IC ICM C12Q

CC 3-3 (Biochemical Genetics)

Section cross-reference(s): 1, 6, 9, 14

IT	473778-25-5	473778-26-6	473778-27-7	473778-28-8	473778-29-9
	473778-30-2	473778-31-3	473778-32-4	473778-33-5	473778-34-6
	473778-35-7	473778-36-8	473778-37-9	473778-38-0	473778-39-1
	473778-40-4	473778-41-5	473778-42-6	473778-43-7	473778-44-8
	473778-45-9	473778-46-0	473778-47-1	473778-48-2	473778-49-3
	473778-50-6	473778-51-7	473778-52-8	473778-53-9	473778-54-0
	473778-55-1	473778-56-2	473778-57-3	473778-58-4	473778-59-5
	473778-60-8	473778-61-9	473778-62-0	473778-63-1	473778-64-2
	473778-65-3	473778-66-4	473778-67-5	473778-68-6	473778-69-7
	473778-70-0	473778-71-1	473778-72-2	473778-73-3	473778-74-4
	473778-75-5	473778-76-6	473778-77-7	473778-78-8	473778-79-9
	473778-80-2	473778-81-3	473778-82-4	473778-83-5	473778-84-6
	473778-85-7	473778-86-8	473778-87-9	473778-88-0	473778-89-1
	473778-90-4	473778-91-5	473778-92-6	473778-93-7	473778-94-8
	473778-95-9	473778-96-0	473778-97-1	473778-98-2	473778-99-3
	473779-00-9	473779-01-0	473779-02-1	473779-03-2	473779-04-3
	473779-05-4	473779-06-5	473779-07-6	473779-08-7	473779-09-8
	473779-10-1	473779-11-2	473779-12-3	473779-13-4	473779-14-5
	473779-15-6	473779-16-7	473779-17-8	473779-18-9	473779-19-0
	473779-20-3	473779-21-4	473779-22-5	473779-23-6	473779-24-7
	473779-25-8	473779-26-9	473779-27-0	473779-28-1	473779-29-2
	473779-30-5	473779-31-6	473779-32-7	473779-33-8	473779-34-9
	473779-35-0	473779-36-1	473779-37-2	473779-38-3	473779-39-4
	473779-40-7	473779-41-8	473779-42-9	473779-43-0	473779-44-1
	473779-45-2	473779-46-3	473779-47-4	473779-48-5	473779-49-6
	473779-50-9	473779-51-0	473779-52-1	473779-53-2	473779-54-3
	473779-55-4	473779-56-5	473779-57-6	473779-58-7	473779-59-8
	473779-60-1	473779-61-2	473779-62-3	473779-63-4	473779-64-5
	473779-65-6	473779-66-7	473779-67-8	473779-68-9	473779-69-0
	473779-70-3	473779-71-4	473779-72-5	473779-73-6	473779-74-7
	473779-75-8	473779-76-9	473779-77-0	473779-78-1	473779-79-2
	473779-80-5	473779-81-6	473779-82-7	473779-83-8	473779-84-9
	473779-85-0	473779-86-1	473779-87-2	473779-88-3	473779-89-4
	473779-90-7	473779-91-8	473779-92-9	473779-93-0	473779-94-1
	473779-95-2	473779-96-3	473779-97-4	473779-98-5	473779-99-6
	473780-00-6	473780-01-7	473780-02-8	473780-03-9	473780-04-0
	473780-05-1	473780-06-2	473780-07-3	473780-08-4	473780-09-5
	473780-10-8	473780-11-9	473780-12-0	473780-13-1	473780-14-2
	473780-15-3	473780-16-4	473780-17-5	473780-18-6	473780-19-7
	473780-20-0	473780-21-1	473780-22-2	473780-23-3	473780-24-4
	473780-25-5	473780-26-6	473780-27-7	473780-28-8	473780-29-9

473780-30-2 473780-31-3 **473780-32-4** 473780-33-5
 473780-34-6 473780-35-7 473780-36-8 473780-37-9 473780-38-0
 473780-39-1 473780-40-4 473780-41-5 473780-42-6 473780-43-7
 473780-44-8 473780-45-9 473780-46-0 473780-47-1 473780-48-2
 473780-49-3 473780-50-6 473780-51-7 473780-52-8 473780-53-9
 473780-54-0 473780-55-1 473780-56-2

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

IT **473780-32-4**

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)


(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)


RN 473780-32-4 CAPLUS

CN L-Arginine, L-cysteinyl-L-leucyl-L-alanyl-L-cysteinyl-L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





L4 ANSWER 19 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:857442 CAPLUS
 DOCUMENT NUMBER: 137:321377
 TITLE: Human nucleic acids and corresponding proteins useful
 in the detection and treatment of various cancers
 INVENTOR(S): Jakobovits, Aya; Challita-Eid, Pia M.; Faris, Mary;
 Ge, Wangmao; Hubert, Rene S.; Morrison, Karen;
 Morrison, Robert Kendall; Raitano, Arthur B.
 PATENT ASSIGNEE(S): Agensys, Inc., USA
 SOURCE: PCT Int. Appl., 1021 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 30
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083921	A2	20021024	WO 2002-XB11654	20020410
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2002083921	A2	20021024	WO 2002-US11654	20020410
WO 2002083921	C1	20051215		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
US 2005227253	A1	20051013	US 2004-990137	20041115
US 2006018917	A1	20060126	US 2004-989767	20041115

US 2005214211	A1	20050929	US 2005-73349	20050303
PRIORITY APPLN. INFO.:			US 2001-282739P	P 20010410
			US 2001-283112P	P 20010410
			US 2001-286630P	P 20010425
			WO 2002-US11654	A 20020410
			US 2000-227098P	P 20000822
			US 2001-300373P	P 20010622
			US 2001-935430	A1 20010822
			US 2002-120835	A3 20020409

ED Entered STN: 12 Nov 2002

AB Eighteen genes and their resp. encoded proteins, and variants thereof, are described wherein the gene exhibits restricted expression in normal adult tissue and is overexpressed in various cancers. Suppression subtractive hybridization (SSH) is used to identify cDNAs corresponding to genes that are differentially expressed in cancer; PCR amplification, cloning, and sequencing of gene fragments from SSH yield the full-length cDNAs. Consequently, the gene products provide diagnostic, prognostic, prophylactic, and/or therapeutic targets for cancer. The genes or fragment thereof, their encoded proteins, or variants or fragments thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with the gene products can be used in active or passive immunization. [This abstract record is one of 16 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IC ICM C12Q

CC 3-3 (Biochemical Genetics)

Section cross-reference(s): 1, 6, 9, 14

IT	473614-58-3	473614-59-4	473614-60-7	473614-61-8	473614-62-9
	473614-63-0	473614-64-1	473614-65-2	473614-66-3	473614-67-4
	473614-68-5	473614-69-6	473614-70-9	473614-71-0	473614-72-1
	473614-73-2	473614-74-3	473614-75-4	473614-76-5	473614-77-6
	473614-78-7	473614-79-8	473614-80-1	473614-81-2	473614-82-3
	473614-83-4	473614-84-5	473614-85-6	473614-86-7	473614-87-8
	473614-88-9	473614-89-0	473614-90-3	473614-91-4	473614-92-5
	473614-93-6	473614-94-7	473614-95-8	473614-96-9	473614-97-0
	473614-98-1	473614-99-2	473615-00-8	473615-01-9	473615-02-0
	473615-03-1	473615-04-2	473615-05-3	473615-06-4	473615-07-5
	473615-08-6	473615-09-7	473615-10-0	473615-11-1	473615-12-2
	473615-13-3	473615-14-4	473615-15-5	473615-16-6	473615-17-7
	473615-18-8	473615-19-9	473615-20-2	473615-21-3	473615-22-4
	473615-23-5	473615-24-6	473615-25-7	473615-26-8	473615-27-9
	473615-28-0	473615-29-1	473615-30-4	473615-31-5	473615-32-6
	473615-33-7	473615-34-8	473615-35-9	473615-36-0	473615-37-1
	473615-38-2	473615-39-3	473615-40-6	473615-41-7	473615-42-8
	473615-43-9	473615-44-0	473615-45-1	473615-46-2	473615-47-3
	473615-48-4	473615-49-5	473615-50-8	473615-51-9	473615-52-0
	473615-53-1	473615-54-2	473615-55-3	473615-56-4	473615-57-5
	473615-58-6	473615-59-7	473615-60-0	473615-61-1	473615-62-2
	473615-63-3	473615-64-4	473615-65-5	473615-66-6	473615-67-7
	473615-68-8	473615-69-9	473615-70-2	473615-71-3	473615-72-4
	473615-73-5	473615-74-6	473615-75-7	473615-76-8	473615-77-9
	473615-78-0	473615-79-1	473615-80-4	473615-81-5	473615-82-6
	473615-83-7	473615-84-8	473615-85-9	473615-86-0	473615-87-1
	473615-88-2	473615-89-3	473615-90-6	473615-91-7	473615-92-8
	473615-93-9	473615-94-0	473615-95-1	473615-96-2	473615-97-3
	473615-98-4	473615-99-5	473616-00-1	473616-01-2	473616-02-3
	473616-03-4	473616-04-5	473616-05-6	473616-06-7	473616-07-8
	473616-08-9	473616-09-0	473616-10-3	473616-11-4	473616-12-5
	473616-13-6	473616-14-7	473616-15-8	473616-16-9	473616-17-0
	473616-18-1	473616-19-2	473616-20-5	473616-21-6	473616-22-7

473616-23-8	473616-24-9	473616-25-0	473616-26-1	473616-27-2
473616-28-3	473616-29-4	473616-30-7	473616-31-8	473616-32-9
473616-33-0	473616-34-1	473616-35-2	473616-36-3	473616-37-4
473616-38-5	473616-39-6	473616-40-9	473616-41-0	473616-42-1
473616-43-2	473616-44-3	473616-45-4	473616-46-5	473616-47-6
473616-48-7	473616-49-8	473616-50-1	473616-51-2	473616-52-3
473616-53-4	473616-54-5	473616-55-6	473616-56-7	473616-57-8
473616-58-9	473616-59-0	473616-60-3	473616-61-4	473616-62-5
473616-63-6	473616-64-7	473616-65-8	473616-66-9	473616-67-0
473616-68-1	473616-69-2	473616-70-5	473616-71-6	473616-72-7
473616-73-8	473616-74-9	473616-75-0	473616-76-1	
473616-77-2	473616-78-3	473616-79-4	473616-80-7	473616-81-8
473616-82-9	473616-83-0	473616-84-1	473616-85-2	473616-86-3
473616-87-4	473616-88-5	473616-89-6		

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

IT	473616-90-9	473616-91-0	473616-92-1	473616-93-2	473616-94-3
	473616-95-4	473616-96-5	473616-97-6	473616-98-7	473616-99-8
	473617-00-4	473617-01-5	473617-02-6	473617-03-7	473617-04-8
	473617-05-9	473617-06-0	473617-07-1	473617-08-2	473617-09-3
	473617-10-6	473617-11-7	473617-12-8	473617-13-9	
	473617-14-0	473617-15-1	473617-16-2	473617-17-3	473617-18-4
	473617-19-5	473617-20-8	473617-21-9	473617-22-0	473617-23-1
	473617-24-2	473617-25-3	473617-26-4	473617-27-5	473617-28-6
	473617-29-7	473617-30-0	473617-31-1	473617-32-2	473617-33-3
	473617-34-4	473617-35-5	473617-40-2	473617-45-7	473617-46-8
	473617-50-4	473617-52-6	473617-53-7	473617-54-8	473617-56-0
	473617-58-2	473617-61-7	473617-65-1	473617-66-2	473617-67-3
	473617-68-4	473617-69-5	473617-70-8	473617-71-9	473617-72-0
	473617-73-1	473617-74-2	473617-75-3	473617-76-4	473617-77-5
	473617-78-6	473617-79-7	473617-80-0	473617-81-1	473617-82-2
	473617-83-3	473617-84-4	473617-85-5	473617-86-6	473617-87-7
	473617-88-8	473617-89-9	473617-90-2	473617-91-3	473617-92-4
	473617-93-5	473617-94-6	473617-95-7	473617-96-8	473617-97-9
	473617-98-0	473617-99-1	473618-00-7	473618-01-8	473618-02-9
	473618-03-0	473618-04-1	473618-05-2	473618-06-3	473618-07-4
	473618-08-5	473618-09-6	473618-10-9	473618-11-0	473618-12-1
	473618-13-2	473618-14-3	473618-15-4	473618-16-5	473618-17-6
	473618-18-7	473618-19-8	473618-20-1	473618-21-2	473618-22-3
	473618-23-4	473618-24-5	473618-25-6	473618-26-7	473618-27-8
	473618-28-9	473618-29-0	473618-30-3	473618-31-4	473618-32-5
	473618-33-6	473618-34-7	473618-35-8	473618-36-9	473618-37-0
	473618-38-1	473618-39-2	473618-40-5	473618-41-6	473618-42-7
	473618-43-8	473618-44-9	473618-45-0	473618-46-1	473618-47-2
	473618-48-3	473618-49-4	473618-50-7	473618-51-8	473618-52-9
	473618-53-0	473618-54-1	473618-55-2	473618-56-3	473618-57-4
	473618-58-5	473618-59-6	473618-60-9	473618-61-0	473618-62-1
	473618-63-2	473618-64-3	473618-65-4	473618-66-5	473618-67-6
	473618-68-7	473618-69-8	473618-70-1	473618-71-2	473618-72-3
	473618-73-4	473618-74-5	473618-75-6	473618-76-7	473618-77-8
	473618-78-9	473618-79-0	473618-80-3	473618-81-4	473618-82-5
	473618-83-6	473618-84-7	473618-85-8	473618-86-9	473618-87-0
	473618-88-1	473618-89-2	473618-90-5	473618-91-6	473618-92-7
	473618-93-8	473618-94-9	473618-95-0	473618-96-1	473618-97-2
	473618-99-4	473619-01-1	473619-02-2	473619-04-4	473619-06-6
	473619-08-8	473619-10-2	473619-12-4	473619-14-6	473619-16-8
	473619-18-0	473619-20-4	473619-22-6	473619-24-8	473619-26-0

473619-28-2 473619-30-6 473619-32-8 473619-34-0 473619-36-2
 473619-38-4 473619-40-8 473619-42-0 473619-44-2 473619-46-4
 473619-48-6 473619-50-0 473619-54-4 473619-56-6 473619-58-8
 473619-60-2 473619-62-4 473619-64-6 473619-66-8 473619-68-0
 473619-70-4 473619-72-6 473619-74-8 473619-76-0 473619-78-2
 473619-80-6 473619-82-8 473619-84-0

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

IT 473616-72-7 473616-73-8 473617-11-7

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)


(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

RN 473616-72-7 CAPLUS

CN L-Arginine, L-glutaminyl-L-isoleucyl-L-cysteinyl-L-leucyl-L-alanyl-L-cysteinyl-L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-lysyl-L-arginyl-L-cysteinyl-L-methionyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 2-A



PAGE 3-A




RN 473616-73-8 CAPLUS


CN L-Cysteine, glycyl-L-valyl-L-glutaminyl-L-isoleucyl-L-cysteinyl-L-leucyl-L-alanyl-L-cysteinyl-L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-lysyl-L-arginyl-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 2-A




PAGE 3-A




RN 473617-11-7 CAPLUS
 CN L-Proline, L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-lysyl-L-arginyl-L-
 cysteinyl-L-methionyl-L-arginyl-L-histidyl-L-alanyl-L-methionyl-L-
 cysteinyl-L-cysteinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A



L4 ANSWER 20 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:814341 CAPLUS
 DOCUMENT NUMBER: 137:334071
 TITLE: Human nucleic acids and corresponding proteins useful
 in the detection and treatment of various cancers
 INVENTOR(S): Jakobovits, Aya; Challita-Eid, Pia M.; Faris, Mary;
 Ge, Wangmao; Hubert, Rene S.; Morrison, Karen;
 Morrison, Robert Kendall; Raitano, Arthur B.
 PATENT ASSIGNEE(S): Agensys, Inc., USA
 SOURCE: PCT Int. Appl., 1021 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English

FAMILY ACC. NUM. COUNT: 30
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083921	A2	20021024	WO 2002-US11654	20020410
WO 2002083921	C1	20051215		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
CA 2443123	AA	20021024	CA 2002-2443123	20020410
WO 2002083921	A2	20021024	WO 2002-XA11654	20020410
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2002083921	A2	20021024	WO 2002-XB11654	20020410
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2002083921	A2	20021024	WO 2002-XC11654	20020410
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2002083921	A2	20021024	WO 2002-XD11654	20020410
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2002083921	A2	20021024	WO 2002-XE11654	20020410
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW			

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, UZ, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 WO 2002083921 A2 20021024 WO 2002-XF11654 20020410
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, UZ, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 WO 2002083921 A2 20021024 WO 2002-XG11654 20020410
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, UZ, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 WO 2002083921 A2 20021024 WO 2002-XH11654 20020410
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, UZ, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 WO 2002083921 A2 20021024 WO 2002-XI11654 20020410
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, UZ, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 WO 2002083921 A2 20021024 WO 2002-XJ11654 20020410
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, UZ, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 WO 2002083921 A2 20021024 WO 2002-XK11654 20020410
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
WO 2002083921 A2 20021024 WO 2002-XL11654 20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
WO 2002083921 A2 20021024 WO 2002-XM11654 20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
WO 2002083921 A2 20021024 WO 2002-XN11654 20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
WO 2002083921 A2 20021024 WO 2002-XO11654 20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2003109470 A1 20030612 US 2002-121019 20020410
EP 1573024 A2 20050914 EP 2002-747813 20020410
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
US 2005227253 A1 20051013 US 2004-990137 20041115
US 2006018917 A1 20060126 US 2004-989767 20041115
US 2005214211 A1 20050929 US 2005-73349 20050303
PRIORITY APPLN. INFO.: US 2001-282739P P 20010410
US 2001-283112P P 20010410
US 2001-286630P P 20010425
US 2000-227098P P 20000822
US 2001-300373P P 20010622

US 2001-935430 A1 20010822
 US 2002-120835 A3 20020409
 WO 2002-US11654 W 20020410

ED Entered STN: 25 Oct 2002

AB Eighteen genes and their resp. encoded proteins, and variants thereof, are described wherein the gene exhibits restricted expression in normal adult tissue and is overexpressed in various cancers. Suppression subtractive hybridization (SSH) is used to identify cDNAs corresponding to genes that are differentially expressed in cancer; PCR amplification, cloning, and sequencing of gene fragments from SSH yield the full-length cDNAs. Consequently, the gene products provide diagnostic, prognostic, prophylactic, and/or therapeutic targets for cancer. The genes or fragment thereof, their encoded proteins, or variants or fragments thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with the gene products can be used in active or passive immunization. [This abstract record is one of 16 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IC ICM C12Q

CC 3-3 (Biochemical Genetics)

Section cross-reference(s): 1, 6, 9, 14

IT	473318-82-0	473318-83-1	473318-84-2	473318-85-3	473318-86-4
	473318-87-5	473318-88-6	473318-89-7	473318-90-0	473318-91-1
	473318-92-2	473318-93-3	473318-94-4	473318-95-5	473318-96-6
	473318-97-7	473318-98-8	473318-99-9	473319-00-5	473319-01-6
	473319-02-7	473319-03-8	473319-04-9	473319-05-0	473319-06-1
	473319-07-2	473319-08-3	473319-09-4	473319-10-7	473319-11-8
	473319-12-9	473319-13-0	473319-14-1	473319-15-2	
	473319-16-3	473319-17-4	473319-18-5	473319-19-6	473319-20-9
	473319-21-0	473319-22-1	473319-23-2	473319-24-3	473319-25-4
	473319-26-5	473319-27-6	473319-28-7	473319-29-8	473319-30-1
	473319-31-2	473319-32-3	473319-33-4	473319-34-5	473319-35-6
	473319-36-7	473319-37-8	473319-38-9	473319-39-0	473319-40-3
	473319-41-4	473319-42-5	473319-43-6	473319-44-7	473319-45-8
	473319-46-9	473319-47-0	473319-48-1	473319-49-2	473319-50-5
	473319-51-6	473319-52-7	473319-53-8	473319-54-9	473319-55-0
	473319-56-1	473319-57-2	473319-58-3	473319-59-4	473319-60-7
	473319-61-8	473319-62-9	473319-63-0	473319-64-1	473319-65-2
	473319-66-3	473319-67-4	473319-68-5	473319-69-6	473319-70-9
	473319-71-0	473319-72-1	473319-73-2	473319-74-3	473319-75-4
	473319-76-5	473319-77-6	473319-78-7	473319-79-8	473319-80-1
	473319-81-2	473319-82-3	473319-83-4	473319-84-5	473319-85-6
	473319-86-7	473319-87-8	473319-88-9	473319-89-0	473319-90-3
	473319-91-4	473319-92-5	473319-93-6	473319-94-7	473319-95-8
	473319-96-9	473319-97-0	473319-98-1	473319-99-2	473320-00-2
	473320-01-3	473320-02-4	473320-03-5	473320-04-6	473320-05-7
	473320-06-8	473320-07-9	473320-08-0	473320-09-1	473320-10-4
	473320-11-5	473320-12-6	473320-13-7	473320-14-8	473320-15-9
	473320-16-0	473320-17-1	473320-18-2	473320-19-3	473320-20-6
	473320-21-7	473320-22-8	473320-23-9	473320-24-0	473320-25-1
	473320-26-2	473320-27-3	473320-28-4	473320-29-5	473320-30-8
	473320-31-9	473320-32-0	473320-33-1	473320-34-2	473320-35-3
	473320-36-4	473320-37-5	473320-38-6	473320-39-7	473320-40-0
	473320-41-1	473320-42-2	473320-43-3	473320-44-4	473320-45-5
	473320-46-6	473320-47-7	473320-48-8	473320-49-9	473320-50-2
	473320-51-3	473320-52-4	473320-53-5	473320-54-6	473320-55-7
	473320-56-8	473320-57-9	473320-58-0	473320-59-1	473320-60-4
	473320-61-5	473320-62-6	473320-63-7	473320-64-8	473320-65-9
	473320-66-0	473320-67-1	473320-68-2	473320-69-3	473320-70-6
	473320-71-7	473320-72-8	473320-73-9	473320-74-0	473320-75-1

473320-76-2 473320-77-3 473320-78-4 473320-79-5 473320-80-8
 473320-81-9 473320-82-0 473320-83-1 473320-84-2 473320-85-3
 473320-86-4 473320-87-5 473320-88-6 473320-89-7 473320-90-0
 473320-91-1 473320-92-2 473320-93-3 473320-94-4 473320-95-5
 473320-96-6 473320-97-7 473320-98-8 473320-99-9 473321-00-5
 473321-01-6 473321-02-7 473321-03-8 473321-04-9 473321-05-0
 473321-06-1 473321-07-2 473321-08-3 473321-09-4 473321-10-7
 473321-11-8 473321-12-9 473321-13-0

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

IT 473319-12-9

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)


(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)


RN 473319-12-9 CAPLUS

CN L-Arginine, L-leucyl-L-alanyl-L-cysteinyl-L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





L4 ANSWER 21 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:657914 CAPLUS
 DOCUMENT NUMBER: 137:206525
 TITLE: Transporters comprising spaced arginine moieties
 INVENTOR(S): Wender, Paul A.; Rothbard, Jonathan B.; Wright, Lee;
 Kreider, Erik L.; Vandeusen, Christopher L.
 PATENT ASSIGNEE(S): Cellgate, Inc., USA; Univ. Leland Stanford Junior
 SOURCE: PCT Int. Appl., 58 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002065986	A2	20020829	WO 2002-US4491	20020214
WO 2002065986	C2	20030313		
WO 2002065986	A3	20040122		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2437983	AA	20020829	CA 2002-2437983	20020214
US 2003032593	A1	20030213	US 2002-78247	20020214
EP 1401473	A2	20040331	EP 2002-742477	20020214
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005508832	T2	20050407	JP 2002-565547	20020214
PRIORITY APPLN. INFO.:			US 2001-269627P	P 20010216
			WO 2002-US4491	W 20020214

OTHER SOURCE(S): MARPAT 137:206525

ED Entered STN: 30 Aug 2002

AB The present invention provides compns. and methods for enhancing transport of biol. active compds. across biol. membranes and across and into animal epithelial or endothelial tissues. The composition includes a biol. active agent and a transport moiety. The transport moiety includes a structure selected from the group consisting of (ZYZ)nZ, (ZY)nZ, (ZYY)nZ and

(ZYYY)nZ. Subunit "Z" is L-arginine or D-arginine, and subunit "Y" is an amino acid that does not comprise an amidino or guanidino moiety. Subscript "n" is an integer ranging from 2 to 10. The method for enhancing transport involves the administration of the aforementioned composition

IC ICM A61K

CC 63-5 (Pharmaceuticals)

Section cross-reference(s): 1, 2

IT 452337-03-0P 452337-04-1P 452337-05-2P 452337-06-3P 452337-07-4P
452337-08-5P 452337-09-6P 452337-10-9P 452337-11-0P 452337-12-1P
452337-13-2P **452337-14-3P** 452337-15-4P 452337-16-5P
452337-17-6P 452337-18-7P 452337-19-8P 452337-20-1P 452337-21-2P
452337-22-3P 452337-23-4P 452337-24-5P 452337-25-6P 452337-26-7P
452337-27-8P 452337-28-9P 452337-29-0P 452337-30-3P 452337-31-4P

RL: PAC (Pharmacological activity); PNU (Preparation, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(cell-membrane drug transporters comprising spaced arginine moieties)

IT **452337-14-3P**

RL: PAC (Pharmacological activity); PNU (Preparation, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(cell-membrane drug transporters comprising spaced arginine moieties)


RN 452337-14-3 CAPLUS

CN L-Argininamide, N2-[6-[[[(3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-5-yl)amino]thioxomethyl]amino]-1-oxohexyl]-L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-lysyl-L-arginyl-L-lysyl-L-arginyl-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A


HO—




PAGE 1-B




PAGE 2-A



PAGE 3-A





L4 ANSWER 22 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:515124 CAPLUS

DOCUMENT NUMBER: 137:210414

TITLE: Arginine-rich molecular transporters for drug delivery: role of backbone spacing in cellular uptake
 AUTHOR(S): Rothbard, Jonathan B.; Kreider, Erik; VanDeusen, Christopher L.; Wright, Lee; Wylie, Bryan L.; Wender, Paul A.

CORPORATE SOURCE: CellGate Inc., Sunnyvale, CA, 94085, USA

SOURCE: Journal of Medicinal Chemistry (2002), 45(17), 3612-3618

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 11 Jul 2002

AB Short oligomers of arginine, either alone or when conjugated to therapeutic agents or large biopolymers, have been shown to cross readily a variety of biol. barriers (e.g., lipid bilayers and epithelial tissue). Mol. modeling suggests that only a subset of the side chain guanidinium groups of these transporters might be required for transport involving contact with a common surface such as a plasma membrane or cell surface receptor. To evaluate this hypothesis, a series of decamers were prepared that incorporated seven arginines and three nonarginine residues. Several of these mixed decamers were comparable to the all arginine decamer in their ability to enter cells. More significantly, these decamers containing seven arginines performed almost without exception better than hepta-arginine itself, suggesting that spacing between residues is also important for transport. The influence of spacing was more fully evaluated with a library of oligomers incorporating seven arginines separated by one or more nonconsecutive, non- α -amino acids. This study led to the identification of a new series of highly efficient mol. transporters.

CC 1-3 (Pharmacology)

Section cross-reference(s): 34, 63

IT 74-79-3DP, L-Arginine, -rich mol. transporters, biological studies

148796-87-6P	165893-48-1P	452337-04-1P	452337-26-7P	452337-28-9P
457632-39-2P	457632-40-5P	457632-41-6P	457632-42-7P	457632-43-8P
457632-44-9P	457632-45-0P	457632-46-1P	457632-47-2P	457632-48-3P
457632-49-4P	457632-50-7P	457632-51-8P	457632-52-9P	457632-53-0P
457632-54-1P	457632-55-2P	457632-56-3P	457632-57-4P	457632-58-5P

457632-59-6P 457632-60-9P 457632-61-0P 457632-62-1P 457632-63-2P
 457632-64-3P 457632-65-4P 457632-66-5P 457632-67-6P 457632-68-7P
 457632-69-8P 457632-70-1P 457632-71-2P 457632-72-3P 457632-73-4P
 457632-74-5P 457632-75-6P 457632-76-7P 457632-77-8P 457632-78-9P
 457632-79-0P 457632-80-3P 457632-81-4P 457632-84-7P 457632-87-0P
 457632-90-5P 457632-93-8P 457632-96-1P 457632-97-2P 457633-00-0P
 457633-03-3P 457633-06-6P 457633-07-7P 457633-08-8P 457633-09-9P
 457633-10-2P 457633-11-3P 457633-12-4P 457633-13-5P 457633-14-6P
 457633-15-7P 457633-16-8P 457633-17-9P 457633-18-0P 457633-19-1P
 457633-20-4P 457633-21-5P 457633-22-6P 457633-23-7P 457633-24-8P
 457633-25-9P 457633-26-0P 457633-27-1P **457633-28-2P**
 457633-29-3P 457633-30-6P 457633-31-7P 457633-32-8P 457633-33-9P
 457633-34-0P 457633-35-1P 457633-36-2P 457633-37-3P 457633-38-4P
 457633-39-5P 457633-40-8P 457633-41-9P 457633-42-0P 457633-43-1P
 457633-44-2P

RL: PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation);
 BIOL (Biological study); PREP (Preparation)
 (arginine-rich mol. transporters for drug delivery: role of backbone
 spacing in cellular uptake)

IT **457633-28-2P**


RL: PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation);
 BIOL (Biological study); PREP (Preparation)
 (arginine-rich mol. transporters for drug delivery: role of backbone
 spacing in cellular uptake)


RN 457633-28-2 CAPLUS

CN L-Arginine, L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-lysyl-L-arginyl-L-
 arginyl-L-lysyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 23 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:713370 CAPLUS

DOCUMENT NUMBER: 135:277991

TITLE: Modified blood clotting factors for treatment of bleeding or clotting disorder

INVENTOR(S): High, Katherine A.; Margaritis, Paris; Camire, Rodney M.

PATENT ASSIGNEE(S): Children's Hospital of Philadelphia, USA

SOURCE: PCT Int. Appl., 55 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001070763	A1	20010927	WO 2001-US9355	20010322
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2004102388	A1	20040527	US 2001-816688	20010322
PRIORITY APPLN. INFO.:			US 2000-191331P	P 20000322

ED Entered STN: 28 Sep 2001

AB The invention provides compns. including modified blood clotting factors, i.e., Factor VII, Factor IX, and Factor X, that have a non-native proteolytic cleavage site engineered into them allowing intracellular cleavage and secretion of an active form. The compns. are useful in the methods for treating a bleeding or clotting disorder. For example, gene transfer of modified blood coagulation factor VIIa using the AAV-hAAT-ApoE-FVIIa expression vector offers a treatment for hemophilia patients and does not appear to induce production of inhibitory antibodies against FVIIa.

IC ICM C07K001-00

ICS C07K014-00; C07K017-00; C07H021-02; C07H021-04; C12N015-00; C12N015-09; C12N015-63; C12N015-70; C12N015-74; A61K035-12

CC 63-3 (Pharmaceuticals)

Section cross-reference(s): 1, 3

IT 9001-25-6, Blood-coagulation factor VII 9001-28-9, Factor IX

9001-29-0, Blood coagulation factor X 60202-16-6, Protein C

362594-19-2 362594-20-5

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(modified blood clotting factors for treatment of bleeding or clotting disorder)

IT 362594-19-2


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(modified blood clotting factors for treatment of bleeding or clotting disorder)

RN 362594-19-2 CAPLUS


CN L-Arginine, L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 24 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2001:676613 CAPLUS
 DOCUMENT NUMBER: 135:237111
 TITLE: Arginine-rich vascular endothelial growth factor-inhibiting peptides for use in growth and metastasis inhibition of human tumor cells and for use in treating angiogenesis-related diseases
 INVENTOR(S): Chae, Chi Bom; Bae, Dong Goo; Yoon, Wan Hee
 PATENT ASSIGNEE(S): Korea Green Cross Corporation, S. Korea; Postech Foundation
 SOURCE: PCT Int. Appl., 64 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001066127	A1	20010913	WO 1999-KR796	19991221
W: CA, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1162991	A1	20011219	EP 1999-960007	19991221
EP 1162991	B1	20060301		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
AT 318839	E	20060315	AT 1999-960007	19991221
PRIORITY APPLN. INFO.:			EP 1999-960007	A 19991221
			WO 1999-KR796	W 19991221


ED Entered STN: 14 Sep 2001

AB Disclosed are novel peptides inhibitory of the activity of vascular endothelial growth factor (VEGF) and their use in the treatment of angiogenesis-related diseases, including cancer. A combinatorial library of peptides consisting of six amino acid residues were chemical synthesized and, from the library, specific amino acid residues for each amino acid position were screened by comparing their inhibitory activity against VEGF binding to the cell surface receptor. The novel peptide sequences thus obtained bind to VEGF and block the binding of VEGF to its receptors present on the surface of vascular endothelial cells, thereby inhibiting the hormonal activity of VEGF. The peptides inhibit the angiogenesis induced by VEGF and human cancer cells. Also, the peptides inhibit growth and metastasis of human cancer cells transplanted to mice. Thus, the peptides can be used to treat angiogenesis-related diseases, including cancer, diabetic retinopathy, rheumatoid arthritis, etc. Pharmaceutical compns. are also claimed.


IC ICM A61K038-08
 CC 2-10 (Mammalian Hormones)
 Section cross-reference(s): 63
 IT 96337-25-6 281194-44-3 281194-45-4 360764-73-4 **360764-74-5**
 360764-75-6 360764-76-7 360764-77-8 360764-78-9 360764-79-0
 360764-80-3 360764-81-4
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (arginine-rich vascular endothelial growth factor-inhibiting peptides for use in growth and metastasis inhibition of human tumor cells and for use in treating angiogenesis-related diseases)
 IT **360764-74-5**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (arginine-rich vascular endothelial growth factor-inhibiting peptides for use in growth and metastasis inhibition of human tumor cells and for use in treating angiogenesis-related diseases)
 RN 360764-74-5 CAPLUS
 CN L-Arginine, L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 25 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2001:24174 CAPLUS
 DOCUMENT NUMBER: 135:133967

TITLE: Labeling and distribution of linear peptides identified using in vivo phage display selection for tumors

AUTHOR(S): Kennel, S. J.; Mirzadeh, S.; Hurst, G. B.; Foote, L. J.; Lankford, T. K.; Glowienka, K. A.; Chappell, L. L.; Kelso, J. R.; Davern, S. M.; Safavy, A.; Brechbiel, M. W.

CORPORATE SOURCE: Division of Life Sciences, Oak Ridge National Laboratory, Oak Ridge, TN, USA

SOURCE: Nuclear Medicine and Biology (2000), 27(8), 815-825
CODEN: NMBIEO; ISSN: 0969-8051

PUBLISHER: Elsevier Science Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 10 Jan 2001

AB To develop targeting mols. to be used for vascular targeting of short half-lived α -emitters for radioimmunotherapy, linear peptide phage display libraries were selected in vivo for binding to IC-12 rat tracheal tumors growing in severe combined immune deficient mice. After three rounds of selection, 15 phage clones were analyzed for DNA sequence, and the deduced translation products of cDNA inserts were compared. Three consensus sequences were chosen from three sep. exptl. selection series and peptides of these sequences with added -gly-gly-tyr were obtained. Peptides were radiolabeled on tyrosine with ^{125}I and the biodistribution in tumor-bearing mice was determined. The radioiodinated peptides were stable in vitro and when injected in tumor-bearing mice .apprx.3.0 %ID/g accumulated in the tumor; however, much of the ^{125}I was found in the gastrointestinal tract and thyroid, indicative of dehalogenation of the labeled peptide. Radiolabeling peptide 2 with N-succinimidyl-3- ^{125}I -iodobenzoate resulted in faster excretion, which in turn resulted in lower levels in tumor and other organs, especially thyroid and gastrointestinal tract.

Peptide 2 was derivatized with the bifunctional isothiocyanates of cyclohexyl-B diethylenetriaminepentaacetic acid (DTPA) or CHX-A'' DTPA by direct conjugation or with a hydroxylamine derivative of 1B4M-DTPA (2-(p-[O-(carboxymethyl)hydroxylamine]benzyl)-6-methyl-diethylenetriamine-N,N,N',N'',N'''-pentaacetic acid) coupled at the N-terminus. The primary mol. species in the conjugated products were shown by mass spectrometry to have one DTPA per peptide. Peptide chelate conjugates were radiolabeled with ^{213}Bi and the products tested for biodistribution in tumor-bearing mice. The data show that chelation of ^{213}Bi to peptides was accomplished by both the direct method of DTPA attachment and by the method using the linker at the N-terminus. Only small amts. of peptide accumulated at tumor sites. We conclude that phage display is a powerful tool to select peptides with restricted binding specificity; however, the peptides isolated to date do not bind with high retention to tumor sites in vivo.

CC 8-9 (Radiation Biochemistry)
Section cross-reference(s): 34

IT 14158-31-7DP, Iodine ^{125}I , peptides labeled with, biological studies
15776-20-2DP, Bismuth ^{213}Bi , peptides labeled with, biological studies
352036-17-ODP, radiolabeled conjugates 352036-18-1DP, radiolabeled conjugates
352036-19-2DP, radiolabeled conjugates
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
(labeling and distribution of linear peptides identified using in vivo phage display selection for tumors)

IT 352036-18-1DP, radiolabeled conjugates
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP

(Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)



(labeling and distribution of linear peptides identified using in vivo phage display selection for tumors)

RN 352036-18-1 CAPLUS


CN L-Tyrosine, L-leucyl-L-arginyl-L-isoleucyl-L-lysyl-L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-lysyl-L-arginyl-L-lysyl-L-lysyl-L-threonyl-L-arginyl-L-lysylglycylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 2-A



PAGE 2-B



PAGE 3-A



REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 26 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1996:422979 CAPLUS

DOCUMENT NUMBER: 125:131846

TITLE: Synthesis and cytotoxic activity of peptides containing basic amino acids residues

AUTHOR(S): Chillemi, Francesco; Francescato, Pierangelo; Bossa, Rosaria; Fraccari, Alessandra; Galatulas, Iraklis

CORPORATE SOURCE: Dipartimenti di Chimica Organica e Industriale, Universita di Milano, Milan, 20133, Italy

SOURCE: Anticancer Research (1996), 16(2), 715-716
CODEN: ANTRD4; ISSN: 0250-7005

PUBLISHER: Anticancer Research

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 18 Jul 1996

AB We synthesized eight peptides containing from three to twenty residues of arginine, lysine and histidine, using an automated synthesizer and Fmoc strategy. All peptides were purified by preparative reverse-phase HPLC and characterized by electrospray mass spectrometry. Cytotoxic activity was assessed on HeLa cells. One peptide inhibited the colony-forming ability of tumor cells.

CC 1-6 (Pharmacology)

IT 179753-43-6P 179753-44-7P 179753-45-8P 179753-46-9P

179753-47-0P 179753-48-1P 179753-49-2P 179753-50-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

acid (preparation and antitumor cytotoxicity of peptides containing basic amino residues)

IT 179753-47-0P 179753-48-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


acid (preparation and antitumor cytotoxicity of peptides containing basic amino residues)

RN 179753-47-0 CAPLUS


CN L-Lysine, L-lysyl-L-arginyl-L-histidyl-L-arginyl-L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-histidyl-L-arginyl-L-lysyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



PAGE 1-C




PAGE 2-A



CC(=O)N


CN L-Lysine, L-arginyl-L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-lysyl-L-
arginyl-L-arginyl-L-lysyl-L-arginyl-L-arginyl-L-lysyl-L-arginyl-L-arginyl-
L-arginyl- (9CI) (CA INDEX NAME)

PAGE 1-A




The image shows two chemical structures. The top structure is 3-aminopropylamine, represented as $\text{---}(\text{CH}_2)_3\text{---NH---CH(=NH)NH}_2$. The bottom structure is 3-aminopropylamide, represented as $\text{---}(\text{CH}_2)_3\text{---NH---CH(=NH)NH}_2$ with a carbonyl group (C=O) attached to the nitrogen of the amide group.

PAGE 2-A



PAGE 3-A



=>